{"entity":{"id":"2024","kind":"year","name":"2024 in oncology","aka":["2024"],"tldr":"Everything OnCo dates to 2024: 702 entries, 141 landmarks, 131 papers, 112 trials reported and 91 papers listed on people's pages. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"702 dated entries in OnCo fall in 2024: 141 landmarks, 131 papers, 112 trials reported, 91 papers listed on people's pages, 84 approvals, 69 regulatory events, 31 financing rounds, 28 technologies, 10 guideline changes, 3 expected dates and 2 laws and regulations.\n\nOf those, 50 to the day, 30 to the month and 622 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2023","2025"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2024,"events":[{"group":"approval","date":"2024","precision":"year","title":"Adagrasib approved in EU","note":"KRAS G12C NSCLC after ≥1 line; 5 Jan 2024 (conditional). Conditional marketing authorisation","from":"adagrasib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Adagrasib approved in US","note":"KRAS G12C colorectal cancer with cetuximab","from":"adagrasib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Adagrasib approved in US","note":"KRAS G12C-mutated locally advanced or metastatic colorectal cancer after fluoropyrimidine, oxaliplatin and irinotecan chemotherapy, with cetuximab.","from":"adagrasib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Afamitresgene autoleucel approved in US","note":"Advanced MAGE-A4+ synovial sarcoma, HLA-A*02+ (age ≥12 from 2026)","from":"afamitresgene-autoleucel","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Alectinib approved in US","note":"Adjuvant ALK+ NSCLC after resection (stage IB ≥4 cm to IIIA)","from":"alectinib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Amivantamab approved in US","note":"First-line EGFR-mutant NSCLC with lazertinib","from":"amivantamab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Asciminib approved in US","note":"Newly diagnosed Ph+ CML in chronic phase (ASC4FIRST)","from":"asciminib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Benmelstobart approved in CN","note":"Extensive-stage small-cell lung cancer, first line, with anlotinib and platinum-etoposide chemotherapy","from":"benmelstobart","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Blinatumomab approved in US","note":"Consolidation in CD19+ B-ALL regardless of MRD","from":"blinatumomab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Cadonilimab approved in China","note":"First-line persistent/recurrent/metastatic cervical cancer with chemotherapy ± bevacizumab; first-line gastric cancer with chemotherapy","from":"cadonilimab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Capivasertib approved in EU","note":"ER+/HER2- mBC with PIK3CA/AKT1/PTEN alteration; 17 Jun 2024","from":"capivasertib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Cetuximab approved in US","note":"KRAS G12C mCRC with adagrasib","from":"cetuximab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Ciltacabtagene autoleucel approved in US","note":"Relapsed myeloma after ≥1 line, lenalidomide-refractory","from":"ciltacabtagene-autoleucel","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Cologuard Plus approved in US","note":"Colorectal cancer screening in average-risk adults aged 45 and older","from":"cologuard-plus","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Cosibelimab approved in US","note":"Metastatic or locally advanced cutaneous SCC not curable by surgery or radiation","from":"cosibelimab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Crizotinib approved in England (NICE)","note":"ROS1-positive advanced non-small-cell lung cancer in patients who have not had a ROS1 inhibitor.","from":"crizotinib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Daratumumab approved in US","note":"Newly diagnosed transplant-eligible with VRd (PERSEUS)","from":"daratumumab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Denileukin diftitox approved in US","note":"Relapsed or refractory stage I to III CTCL after at least one systemic therapy (Lymphir)","from":"denileukin-diftitox","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Dostarlimab approved in US","note":"Primary advanced/recurrent endometrial cancer with chemotherapy (all-comers)","from":"dostarlimab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Durvalumab approved in UK","note":"Locally advanced, unresectable or metastatic biliary tract cancer with gemcitabine and cisplatin; NICE TA944 recommended 10 January 2024 with a commercial arrangement.","from":"durvalumab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Efbemalenograstim alfa approved in EU","note":"Reduction in duration of neutropenia and febrile neutropenia after cytotoxic chemotherapy in adults (excluding CML and MDS)","from":"efbemalenograstim-alfa","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Encorafenib approved in US","note":"Metastatic colorectal cancer with a BRAF V600E mutation, with cetuximab and mFOLFOX6, previously untreated. Accelerated approval on 20 December 2024 on BREAKWATER.","from":"encorafenib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Ensartinib approved in US","note":"ALK-positive locally advanced or metastatic NSCLC, ALK-inhibitor-naive","from":"ensartinib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Epcoritamab approved in US","note":"Relapsed/refractory follicular lymphoma after ≥2 lines (accelerated; full 2025 with R2)","from":"epcoritamab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Erdafitinib approved in US","note":"FGFR3-altered advanced urothelial cancer after ≥1 systemic therapy incl. PD-1/PD-L1 (full)","from":"erdafitinib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Fruquintinib approved in EU","note":"Previously treated metastatic colorectal cancer. Fruzaqla marketing authorisation issued 20 June 2024.","from":"fruquintinib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Fulzerasib approved in China","note":"KRAS G12C-mutant advanced NSCLC after at least one systemic therapy","from":"fulzerasib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Futibatinib approved in UK","note":"Locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement after at least one systemic treatment; NICE TA1005 recommended 11 September 2024 as an alternat...","from":"futibatinib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Garsorasib approved in China","note":"KRAS G12C-mutant advanced NSCLC after at least one systemic therapy","from":"garsorasib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Glecirasib approved in CN","note":"KRAS G12C-mutant advanced non-small cell lung cancer after prior systemic therapy","from":"glecirasib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Golidocitinib approved in CN","note":"Relapsed or refractory peripheral T-cell lymphoma","from":"golidocitinib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Idecabtagene vicleucel approved in US","note":"After ≥2 lines including IMiD, PI, and anti-CD38","from":"idecabtagene-vicleucel","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Imetelstat approved in US","note":"Low- to intermediate-1-risk MDS with transfusion-dependent anaemia after ESA failure","from":"imetelstat","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Inavolisib approved in US","note":"PIK3CA-mutant HR+/HER2- advanced breast cancer with palbociclib and fulvestrant","from":"inavolisib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Inotuzumab ozogamicin approved in US","note":"Paediatric patients ≥1 year with relapsed/refractory CD22+ B-ALL","from":"inotuzumab-ozogamicin","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Iparomlimab and tuvonralimab approved in CN","note":"Recurrent or metastatic cervical cancer after platinum chemotherapy","from":"iparomlimab-tuvonralimab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Irinotecan (and liposomal irinotecan) approved in US","note":"Liposomal irinotecan in NALIRIFOX first-line metastatic pancreatic cancer","from":"irinotecan","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Isatuximab approved in US","note":"Newly diagnosed transplant-ineligible with VRd (IMROZ)","from":"isatuximab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Ivonescimab approved in China","note":"EGFR-mutant NSCLC after TKI (with chemotherapy); first-line PD-L1+ NSCLC","from":"ivonescimab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Ivosidenib approved in UK","note":"Locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation after one or more systemic treatments; NICE TA948 recommended 31 January 2024 with a commercial arrange...","from":"ivosidenib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Lazertinib approved in US","note":"First-line EGFR exon 19 del / L858R NSCLC with amivantamab","from":"lazertinib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Lifileucel approved in US","note":"Unresectable/metastatic melanoma after anti-PD-1 (and BRAF/MEK if applicable)","from":"lifileucel","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Limertinib approved in CN","note":"Locally advanced or metastatic EGFR T790M-mutant non-small cell lung cancer after prior EGFR inhibitor therapy","from":"limertinib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Liposomal irinotecan approved in US","note":"First-line metastatic pancreatic adenocarcinoma in NALIRIFOX (NAPOLI 3). FDA label (DailyMed)","from":"liposomal-irinotecan","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Lisocabtagene maraleucel approved in US","note":"Relapsed/refractory CLL/SLL after BTK inhibitor and BCL-2 inhibitor (accelerated)","from":"lisocabtagene-maraleucel","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Lutetium-177 dotatate approved in US","note":"Paediatric ≥12 years; first-line (NETTER-2 label)","from":"lutathera","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Mavorixafor approved in US","note":"WHIM syndrome (warts, hypogammaglobulinaemia, infections and myelokathexis) in patients aged 12 and over","from":"mavorixafor","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"MI Cancer Seek approved in US","note":"Companion diagnostic claims across several solid tumours, with tumour-profiling claims","from":"caris-mi-cancer-seek","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Mirvetuximab soravtansine approved in EU","note":"FRα+ platinum-resistant ovarian; 14 Nov 2024","from":"mirvetuximab-soravtansine","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Momelotinib approved in EU","note":"Myelofibrosis with moderate-to-severe anaemia","from":"momelotinib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) approved in US","note":"First-line metastatic pancreatic adenocarcinoma","from":"nalirifox","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Nogapendekin alfa inbakicept approved in US","note":"BCG-unresponsive NMIBC with CIS ± papillary tumours, with BCG","from":"nogapendekin-alfa","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Obecabtagene autoleucel approved in US","note":"Relapsed or refractory B-cell precursor ALL, adults","from":"obecabtagene-autoleucel","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Odronextamab approved in EU","note":"R/R DLBCL and follicular lymphoma after ≥2 lines (conditional)","from":"odronextamab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Optune / Optune Pax (TTFields) approved in US","note":"Metastatic NSCLC after platinum with PD-1 or docetaxel","from":"optune","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Pegulicianine approved in US","note":"Fluorescence imaging in adults with breast cancer as an adjunct for intraoperative detection of residual cancer after lumpectomy","from":"pegulicianine","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Pembrolizumab approved in England (NICE)","note":"Resectable non-small-cell lung cancer at high risk of recurrence, neoadjuvant with platinum chemotherapy then adjuvant alone.","from":"pembrolizumab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Ponatinib approved in US","note":"Newly diagnosed Ph+ ALL with chemotherapy (accelerated)","from":"ponatinib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Remestemcel-L approved in US","note":"Steroid-refractory acute graft-versus-host disease in children aged two months and older","from":"remestemcel-l","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Repotrectinib approved in US","note":"NTRK-fusion solid tumours (tumour-agnostic)","from":"repotrectinib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Retifanlimab approved in EU","note":"Merkel cell carcinoma","from":"retifanlimab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Revumenib approved in US","note":"Relapsed/refractory KMT2A-rearranged acute leukaemia, age ≥1","from":"revumenib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Ribociclib approved in US","note":"Adjuvant stage II-III HR+/HER2- breast cancer at high risk of recurrence","from":"ribociclib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Sacituzumab tirumotecan approved in China","note":"Pretreated advanced TNBC; later EGFR-mutant NSCLC after TKI","from":"sacituzumab-tirumotecan","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Shield approved in US","note":"Colorectal cancer screening, average-risk adults ≥45","from":"shield","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Sugemalimab approved in EU","note":"First-line metastatic NSCLC with platinum chemotherapy, no sensitising EGFR, ALK, ROS1 or RET alterations","from":"sugemalimab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Talazoparib approved in UK","note":"HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations after an anthracycline or a taxane; NICE TA952 (21 February 2024) recommends withi...","from":"talazoparib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Tarlatamab approved in US","note":"Extensive-stage SCLC after platinum chemotherapy","from":"tarlatamab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Tislelizumab approved in US","note":"Second-line ESCC after chemotherapy; first-line HER2-negative gastric/GEJ with chemotherapy (PD-L1 ≥1)","from":"tislelizumab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Tovorafenib approved in US","note":"Relapsed/refractory BRAF-altered paediatric low-grade glioma (accelerated)","from":"tovorafenib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Trastuzumab deruxtecan approved in UK","note":"HER2-low metastatic or unresectable breast cancer after chemotherapy: NICE TA992 (29 July 2024) does not recommend trastuzumab deruxtecan, the cost per quality-adjusted life year b...","from":"trastuzumab-deruxtecan","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Trastuzumab deruxtecan approved in US","note":"HER2 IHC3+ solid tumours (tumour-agnostic)","from":"trastuzumab-deruxtecan","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Trastuzumab deruxtecan approved in US","note":"Unresectable or metastatic HER2-positive (IHC 3+) solid tumours after previous systemic treatment, including colorectal cancer.","from":"trastuzumab-deruxtecan","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Trifluridine/tipiracil approved in England (NICE)","note":"Metastatic colorectal cancer after two lines of treatment, with bevacizumab. TA1008, published 25 September 2024, recommends the combination within its marketing authorisation subj...","from":"trifluridine-tipiracil","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"TruSight Oncology Comprehensive approved in US","note":"Companion diagnostic for larotrectinib (NTRK fusions) with tumour-profiling claims","from":"trusight-oncology-comprehensive","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Tunlametinib approved in CN","note":"Advanced NRAS-mutant melanoma after prior immunotherapy","from":"tunlametinib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Varnimcabtagene autoleucel approved in IN","note":"Relapsed or refractory B-cell lymphoma. CDSCO market authorisation as announced by Immuneel; ARI-0001 is separately approved in Spain under the hospital exemption","from":"varnimcabtagene-autoleucel","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Vorasidenib approved in US","note":"Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12","from":"vorasidenib","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Zanidatamab approved in US","note":"HER2+ (IHC 3+) unresectable/metastatic biliary tract cancer, previously treated. Ziihera label (openFDA); 53% of HERIZON-BTC-01 patients had gallbladder cancer: https://api.fda.gov...","from":"zanidatamab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Zenocutuzumab approved in US","note":"NRG1-fusion NSCLC and pancreatic adenocarcinoma","from":"zenocutuzumab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Zevorcabtagene autoleucel approved in China","note":"Relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory agent","from":"zevorcabtagene-autoleucel","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Zolbetuximab approved in EU","note":"1L CLDN18.2+ HER2- gastric/GEJ; 19 Sep 2024","from":"zolbetuximab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Zolbetuximab approved in Japan","note":"CLDN18.2+ HER2- gastric cancer (first approval, March 2024)","from":"zolbetuximab","refs":[]},{"group":"approval","date":"2024","precision":"year","title":"Zolbetuximab approved in US","note":"First-line CLDN18.2+ (≥75%), HER2- locally advanced/metastatic gastric or GEJ adenocarcinoma with fluoropyrimidine/platinum chemotherapy","from":"zolbetuximab","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Adcendo: Series B","note":"$135m","from":"adcendo","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Affini-T Therapeutics: Form D offering","note":"$18m. Equity offering, first sale 31 July 2024","from":"affini-t-therapeutics","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Alentis Therapeutics: Series D","note":"$181m","from":"alentis-therapeutics","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Alpha-9 Oncology: Series C","note":"$175m","from":"alpha-9-oncology","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Boundless Bio: IPO","note":"$100m. 6.25 million shares at 16 US dollars; closed 2 April 2024","from":"boundless-bio","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"C2i Genomics: Acquisition","note":"$70m. $70 million in Veracyte shares at closing plus up to $25 million in milestone payments over two years; definitive agreement announced 8 January 2024.","from":"c2i-genomics","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Capstan Therapeutics: Form D offering","note":"$87m. Amount sold at filing of a $175 million offering, first sale 5 March 2024","from":"capstan-therapeutics","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Carevive Systems: Acquisition","note":"$22m. Health Catalyst acquired Carevive Systems on 24 May 2024 for USD 18.6 million net cash, USD 2.6 million in shares and USD 0.9 million contingent earn out; announced 6 June 20...","from":"carevive-systems","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Deep 6 AI: Form D offering","note":"$6m. Late filing made 20 November 2024 for an equity offering first sold 29 November 2017; includes USD 3.4 million of converted notes","from":"deep-6-ai","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Deep 6 AI: Form D offering","note":"$17m. Late filing made 20 November 2024 for an equity offering first sold 17 September 2019; includes USD 6.1 million of converted notes","from":"deep-6-ai","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Deep 6 AI: Form D offering","note":"$27m. Late filing made 20 November 2024 for an equity offering first sold 26 April 2022; USD 26.9 million sold of USD 33.8 million","from":"deep-6-ai","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Enlaza Therapeutics: Series A","note":"$100m. Led by the Life Sciences group of J.P. Morgan Private Capital","from":"enlaza-therapeutics","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Firefly Bio: Series A","note":"$94m","from":"firefly-bio","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Halda Therapeutics: Form D offering","note":"$24m. Total sold of a 36 million US dollar offering per Form D filed May 2024","from":"halda-therapeutics","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Halda Therapeutics: Form D offering","note":"$126m. Total sold per Form D filed August 2024","from":"halda-therapeutics","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Harpoon Therapeutics: Acquisition","note":"$680m. $23.00 per share in cash, approximate total equity value $680 million; announced 8 January 2024, completed 11 March 2024","from":"harpoon-therapeutics","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Inhibrx Biosciences: Acquisition","note":"$2.2bn. Predecessor Inhibrx, Inc. sold its INBRX-101 (alpha-1 antitrypsin) asset to Sanofi for about 2.2 billion US dollars aggregate value; oncology assets were spun out into Inhi...","from":"inhibrx","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Kheiron Medical Technologies: Acquisition","note":"Acquired by DeepHealth, a wholly owned subsidiary of RadNet, announced 22 October 2024; terms not disclosed.","from":"kheiron-medical-technologies","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Mariana Oncology: Acquisition","note":"$1.0bn. USD 1 billion upfront plus up to USD 750 million in milestones","from":"mariana-oncology","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Noetik: Series A","note":"$40m","from":"noetik","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Onc.AI: Grant","note":"$2m. National Cancer Institute SBIR grant, per company website","from":"onc-ai","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Pheon Therapeutics: Series B","note":"$120m","from":"pheon-therapeutics","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"ProfoundBio: Acquisition","note":"$1.8bn. All-cash deal announced 3 April 2024; Nasdaq copy of the Genmab company announcement","from":"profoundbio","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Radionetics Oncology: Series A","note":"$53m. Brought total raised to USD 82.5 million","from":"radionetics-oncology","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Scorpion Therapeutics: Form D offering","note":"$126m. Total sold of a 150 million US dollar offering per Form D filed July 2024","from":"scorpion-therapeutics","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"SonALAsense: Grant","note":"$46m. ARPA-H award of up to USD 46 million (Dec 2024) for sonodynamic therapy in haematologic malignancies; milestone-contingent","from":"sonalasense","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Treeline Biosciences: Form D offering","note":"$422m. Total sold per Form D filed October 2024","from":"treeline-biosciences","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Universal DX: Series B","note":"Series B closed August 2024 with existing investors including Quest Diagnostics and new investors including Olympus Innovation Ventures; extension amount not disclosed.","from":"universal-dx","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Valar Labs: Series A","note":"$22m. Co-led by DCVC and a16z with existing investor Pear VC, May 2024.","from":"valar-labs","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"Volpara Health: Acquisition","note":"Lunit's November 2025 release states the acquisition of Volpara Health Technologies was completed in 2024; value not stated in the fetched source.","from":"volpara-health","refs":[]},{"group":"funding","date":"2024","precision":"year","title":"ZAP Surgical Systems: Series E","note":"$78m. Led by Qingdao Baheal Medical with participation from other strategic investors","from":"zap-surgical-systems","refs":[]},{"group":"history","date":"2024","precision":"year","title":"Adjuvant ribociclib (NATALEE); inavolisib approved","note":"HR-positive / HER2-negative breast cancer","from":"breast-hr-positive","refs":["natalee","inavolisib","inavo120"]},{"group":"history","date":"2024","precision":"year","title":"ADRIATIC: durvalumab after chemoradiation lengthens survival by almost two years; FDA approval","note":"Limited-stage small-cell lung cancer","from":"limited-stage-sclc","refs":["adriatic","durvalumab","cheng-ying","paper-adriatic-nejm-2024"]},{"group":"history","date":"2024","precision":"year","title":"Afami-cel: first TCR-T for a solid tumour","note":"Sarcomas (soft tissue, bone, GIST)","from":"sarcoma","refs":["afamitresgene-autoleucel"]},{"group":"history","date":"2024","precision":"year","title":"Afami-cel: first TCR-T for a solid tumour; MOTION positive; IGNYTE-ESO reports","note":"Sarcomas (soft tissue, bone, GIST)","from":"sarcoma","refs":["afamitresgene-autoleucel","motion","ignyte-eso"]},{"group":"history","date":"2024","precision":"year","title":"Afamitresgene autoleucel approved: first TCR therapy for a solid tumour","note":"Synovial sarcoma","from":"synovial-sarcoma","refs":["afamitresgene-autoleucel"]},{"group":"history","date":"2024","precision":"year","title":"ALINA: adjuvant alectinib for ALK-positive disease; CheckMate 77T perioperative nivolumab approved","note":"Resectable stage I to III non-small-cell lung cancer","from":"resectable-nsclc","refs":["alina","alectinib","nct04025879","tina-cascone"]},{"group":"history","date":"2024","precision":"year","title":"ALINA: two years of adjuvant alectinib cuts recurrence by 76 percent","note":"ALK-positive non-small-cell lung cancer","from":"alk-positive-nsclc","refs":["alina","alectinib","wu-yi-long"]},{"group":"history","date":"2024","precision":"year","title":"All-comers approvals: pembrolizumab (June), dostarlimab (August), durvalumab dMMR (June); T-DXd tumour-agnostic HER2 approval; RUBY overall survival benefit","note":"Endometrial cancer","from":"endometrial","refs":["pembrolizumab","dostarlimab","durvalumab","trastuzumab-deruxtecan"]},{"group":"history","date":"2024","precision":"year","title":"Alliance A071601 published","note":"Craniopharyngioma. Vemurafenib plus cobimetinib produces responses in nearly all BRAF V600E papillary craniopharyngiomas (Lancet Oncology).","from":"craniopharyngioma","refs":["vemurafenib","cobimetinib"]},{"group":"history","date":"2024","precision":"year","title":"Anktiva (N-803 + BCG) approved; erdafitinib full approval (THOR)","note":"Bladder & urothelial cancer","from":"urothelial","refs":["nogapendekin-alfa","thor"]},{"group":"history","date":"2024","precision":"year","title":"AQUILA: daratumumab monotherapy delays progression in high-risk disease","note":"Smouldering multiple myeloma","from":"smouldering-myeloma","refs":["daratumumab"]},{"group":"history","date":"2024","precision":"year","title":"ARST1431: temsirolimus + chemotherapy improves EFS in intermediate risk","note":"Rhabdomyosarcoma","from":"rhabdomyosarcoma","refs":["temsirolimus"]},{"group":"history","date":"2024","precision":"year","title":"ASC4FIRST: asciminib approved for newly diagnosed chronic phase","note":"Chronic myeloid leukaemia, chronic phase","from":"cml-chronic-phase","refs":["asciminib","nct04971226"]},{"group":"history","date":"2024","precision":"year","title":"Asciminib first line","note":"Chronic myeloid leukaemia (CML). ASC4FIRST: higher MMR at 48 weeks than investigator-selected TKI; FDA accelerated approval October 2024.","from":"cml","refs":["asciminib"]},{"group":"history","date":"2024","precision":"year","title":"ASCO guideline on small bowel adenocarcinoma","note":"Small intestine cancer (small bowel adenocarcinoma)","from":"small-bowel","refs":["capox","folfox"]},{"group":"history","date":"2024","precision":"year","title":"AUGMENT-101: revumenib, the first menin inhibitor, approved for relapsed KMT2A-rearranged leukaemia","note":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","from":"aml-npm1-kmt2a","refs":["augment-101","revumenib"]},{"group":"history","date":"2024","precision":"year","title":"BEAT-meso misses OS; non-epithelioid subgroup benefits","note":"Mesothelioma","from":"mesothelioma","refs":["beat-meso"]},{"group":"history","date":"2024","precision":"year","title":"Blinatumomab approved for consolidation of newly diagnosed CD19-positive B-ALL","note":"Standard-risk B-cell acute lymphoblastic leukaemia in children","from":"all-paediatric-standard-risk","refs":["blinatumomab","e1910"]},{"group":"history","date":"2024","precision":"year","title":"Blinatumomab approved for consolidation of newly diagnosed CD19-positive B-ALL","note":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","from":"all-paediatric-high-risk","refs":["blinatumomab","e1910"]},{"group":"history","date":"2024","precision":"year","title":"Blinatumomab consolidation approved for adults and children with B-ALL after E1910","note":"Adolescent and young adult cancers (ages 15 to 39)","from":"aya-cancers","refs":["blinatumomab","e1910"]},{"group":"history","date":"2024","precision":"year","title":"Blinatumomab frontline","note":"Acute lymphoblastic leukaemia","from":"all-leukemia","refs":[]},{"group":"history","date":"2024","precision":"year","title":"Blinatumomab frontline (E1910, AALL1731), ponatinib frontline (PhALLCON), obe-cel approved","note":"Acute lymphoblastic leukaemia. Immunotherapy becomes part of standard first-line therapy for adults and children; second CAR-T for adult ALL; revumenib approved for KMT2Ar leukaemi...","from":"all-leukemia","refs":["e1910","aall1731","phallcon","obecabtagene-autoleucel"]},{"group":"history","date":"2024","precision":"year","title":"BREAKWATER: encorafenib-cetuximab-FOLFOX first line; accelerated approval in December","note":"BRAF V600E-mutant colorectal cancer","from":"braf-v600e-colorectal","refs":["breakwater"]},{"group":"history","date":"2024","precision":"year","title":"BRUIN CLL-321 reads out; lisocabtagene maraleucel approved for double-refractory CLL","note":"Relapsed or refractory chronic lymphocytic leukaemia","from":"cll-relapsed","refs":["bruin-cll-321","lisocabtagene-maraleucel","transcend-cll-004"]},{"group":"history","date":"2024","precision":"year","title":"CABINET published with lung and thymic tumours in the extra-pancreatic cohort","note":"Lung neuroendocrine tumours (typical and atypical carcinoid)","from":"lung-net","refs":["cabinet"]},{"group":"history","date":"2024","precision":"year","title":"Cabozantinib phase 2 reports disease control in advanced adrenocortical carcinoma","note":"Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)","from":"advanced-adrenocortical-carcinoma","refs":["cabozantinib"]},{"group":"history","date":"2024","precision":"year","title":"CheckMate 8HW: nivolumab plus ipilimumab cuts progression by 79 percent","note":"Mismatch-repair deficient (MSI-high) colorectal cancer","from":"msi-high-colorectal","refs":["checkmate-8hw"]},{"group":"history","date":"2024","precision":"year","title":"COMET: active monitoring non-inferior at two years","note":"Ductal carcinoma in situ (DCIS). Hwang and colleagues (JAMA, December 2024); first randomised evidence for monitoring low-risk DCIS.","from":"ductal-carcinoma-in-situ","refs":["active-surveillance"]},{"group":"history","date":"2024","precision":"year","title":"CONTINUUM: sintilimab added to chemoradiotherapy improves event-free survival","note":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","from":"locoregionally-advanced-nasopharyngeal-carcinoma","refs":["checkpoint-inhibitor"]},{"group":"history","date":"2024","precision":"year","title":"Cosibelimab approved","note":"Advanced cutaneous squamous cell carcinoma","from":"advanced-cutaneous-scc","refs":["cosibelimab"]},{"group":"history","date":"2024","precision":"year","title":"Cosibelimab approved (December)","note":"Cutaneous squamous cell carcinoma","from":"cutaneous-scc","refs":["cosibelimab"]},{"group":"history","date":"2024","precision":"year","title":"CUPISCO: molecularly guided therapy after induction chemotherapy lengthens progression-free survival","note":"Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)","from":"cup-unfavourable","refs":["cupisco","cgp"]},{"group":"history","date":"2024","precision":"year","title":"CUPISCO: molecularly guided therapy improves PFS (Lancet)","note":"Cancer of unknown primary (CUP)","from":"cancer-of-unknown-primary","refs":["cgp"]},{"group":"history","date":"2024","precision":"year","title":"DESTINY-Breast06: earlier line and HER2-ultralow","note":"HER2-low and HER2-ultralow metastatic breast cancer","from":"her2-low-metastatic-breast-cancer","refs":["destiny-breast06"]},{"group":"history","date":"2024","precision":"year","title":"DESTINY-Breast12: intracranial response in most patients","note":"HER2-positive breast cancer with brain metastases","from":"her2-positive-breast-brain-metastases","refs":["destiny-breast12"]},{"group":"history","date":"2024","precision":"year","title":"DESTINY-Breast12: trastuzumab deruxtecan active in HER2-positive brain metastases","note":"Brain metastases (secondary brain tumours)","from":"secondary-brain-tumours","refs":["trastuzumab-deruxtecan","destiny-breast12"]},{"group":"history","date":"2024","precision":"year","title":"EMERALD-1 and LEAP-012: TACE + systemic therapy improves PFS; HIMALAYA 5-year OS 19.6%","note":"Hepatocellular carcinoma","from":"hcc","refs":["emerald-1","leap-012"]},{"group":"history","date":"2024","precision":"year","title":"Epcoritamab and zanubrutinib-obinutuzumab approved for relapsed FL","note":"Follicular lymphoma","from":"follicular-lymphoma","refs":["epcoritamab","zanubrutinib"]},{"group":"history","date":"2024","precision":"year","title":"ESOPEC: FLOT better than CROSS in adenocarcinoma","note":"Oesophageal and junctional adenocarcinoma","from":"oesophageal-adenocarcinoma","refs":["flot"]},{"group":"history","date":"2024","precision":"year","title":"FDA accelerated approval of adagrasib with cetuximab","note":"KRAS G12C-mutant colorectal cancer","from":"kras-g12c-colorectal","refs":["adagrasib","cetuximab"]},{"group":"history","date":"2024","precision":"year","title":"FDA approves vorasidenib","note":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","from":"oligodendroglioma","refs":["vorasidenib"]},{"group":"history","date":"2024","precision":"year","title":"FDA approves vorasidenib for grade 2 IDH-mutant astrocytoma and oligodendroglioma","note":"Astrocytoma, IDH-mutant (grades 2 to 4)","from":"idh-mutant-astrocytoma","refs":["vorasidenib"]},{"group":"history","date":"2024","precision":"year","title":"First CAR-T in CLL; AMPLIFY presented","note":"Chronic lymphocytic leukaemia. Liso-cel accelerated approval (March); AMPLIFY fixed-duration acalabrutinib-venetoclax at ASH.","from":"cll","refs":["lisocabtagene-maraleucel","transcend-cll-004","amplify"]},{"group":"history","date":"2024","precision":"year","title":"FIRSTMAPPP: sunitinib delays progression","note":"Pheochromocytoma and paraganglioma (PPGL). Baudin and colleagues, Lancet: first randomised trial in metastatic PPGL.","from":"pheochromocytoma-paraganglioma","refs":["sunitinib"]},{"group":"history","date":"2024","precision":"year","title":"FIRSTMAPPP: sunitinib improves progression-free survival; Azedra withdrawn from the market","note":"Metastatic pheochromocytoma and paraganglioma","from":"metastatic-ppgl","refs":["sunitinib","i131-mibg"]},{"group":"history","date":"2024","precision":"year","title":"Genotype reaches the operating theatre and stage III","note":"Lung cancer (all types). ALINA gave adjuvant alectinib after resection of ALK-positive disease (93.8 against 63.0 percent disease-free at two years), LAURA gave osimertinib after c...","from":"lung-cancer","refs":["paper-wu-alina-adjuvant-alectinib-nejm-2024","paper-lu-laura-osimertinib-stage-iii-nejm-2024","paper-mariposa-nejm-2024","paper-adriatic-nejm-2024"]},{"group":"history","date":"2024","precision":"year","title":"HARMONi-2: ivonescimab beats pembrolizumab on progression-free survival in China","note":"PD-L1-high non-small-cell lung cancer without a driver mutation","from":"pdl1-high-nsclc","refs":["harmoni-2","ivonescimab","paper-harmoni-2-lancet-2025","akeso"]},{"group":"history","date":"2024","precision":"year","title":"HD21 (BrECADD) published in Lancet; S1826 in NEJM","note":"Hodgkin lymphoma","from":"hodgkin-lymphoma","refs":["hd21","swog-s1826"]},{"group":"history","date":"2024","precision":"year","title":"IELSG37: radiotherapy can be omitted after complete metabolic response","note":"Primary mediastinal (thymic) large B-cell lymphoma","from":"primary-mediastinal-b-cell-lymphoma","refs":["ielsg37","pet-adapted-therapy"]},{"group":"history","date":"2024","precision":"year","title":"Imetelstat approved","note":"Myelodysplastic syndromes / neoplasms (MDS). IMerge: telomerase inhibitor achieves durable transfusion independence after ESA failure.","from":"mds","refs":["imetelstat"]},{"group":"history","date":"2024","precision":"year","title":"Imetelstat approved after IMerge: the first telomerase inhibitor","note":"Lower-risk myelodysplastic syndromes","from":"mds-lower-risk","refs":["imetelstat"]},{"group":"history","date":"2024","precision":"year","title":"IMROZ and CEPHEUS: quadruplets for fit transplant-ineligible patients","note":"Newly diagnosed multiple myeloma, transplant-ineligible","from":"myeloma-transplant-ineligible","refs":["imroz","cepheus","isatuximab"]},{"group":"history","date":"2024","precision":"year","title":"Inavolisib approved in the first line for PIK3CA-mutant relapse (INAVO120)","note":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","from":"hr-positive-metastatic-post-cdk46","refs":["inavo120","inavolisib"]},{"group":"history","date":"2024","precision":"year","title":"Inotuzumab ozogamicin approved for children with relapsed or refractory CD22-positive B-ALL","note":"Relapsed and refractory acute lymphoblastic leukaemia in children","from":"all-paediatric-relapsed","refs":["inotuzumab-ozogamicin"]},{"group":"history","date":"2024","precision":"year","title":"International Anal Neoplasia Society screening guidelines for people at high risk","note":"Anal high-grade squamous intraepithelial lesions (precursor)","from":"anal-hsil-precursor","refs":["hpv-testing"]},{"group":"history","date":"2024","precision":"year","title":"INTUITT-NF2: brigatinib active across NF2-related tumours","note":"Vestibular schwannoma (acoustic neuroma). Plotkin and colleagues (NEJM) report the first platform trial in the condition.","from":"vestibular-schwannoma","refs":["brigatinib"]},{"group":"history","date":"2024","precision":"year","title":"KEYNOTE-522 overall survival benefit published","note":"Early triple-negative breast cancer","from":"tnbc-early","refs":["keynote-522"]},{"group":"history","date":"2024","precision":"year","title":"KEYNOTE-564 shows OS benefit; CheckMate 214 8-year data; TiNivo-2 negative","note":"Renal cell carcinoma","from":"rcc","refs":["keynote-564","checkmate-214","tinivo-2"]},{"group":"history","date":"2024","precision":"year","title":"KEYNOTE-B21: adjuvant pembrolizumab misses its primary endpoint overall; dMMR subgroup appears to benefit","note":"Mismatch-repair-deficient endometrial cancer","from":"endometrial-mmr-deficient","refs":["nct04634877"]},{"group":"history","date":"2024","precision":"year","title":"KRYSTAL-12: adagrasib beats docetaxel; divarasib enters phase 3 (Krascendo 1)","note":"KRAS G12C-mutant non-small-cell lung cancer","from":"kras-g12c-nsclc","refs":["krystal-12","adagrasib","divarasib","krascendo-1"]},{"group":"history","date":"2024","precision":"year","title":"Kyoto guidelines revise surveillance intervals and add cyst fluid molecular markers","note":"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors","from":"ipmn-cystic-precursors","refs":["endoscopic-ultrasound-systems","ca19-9"]},{"group":"history","date":"2024","precision":"year","title":"LAURA (osimertinib after chemoradiation); HARMONi-2: ivonescimab beats pembrolizumab in China; lazertinib approved","note":"Non-small-cell lung cancer","from":"nsclc","refs":["laura","harmoni-2","lazertinib"]},{"group":"history","date":"2024","precision":"year","title":"LAURA: osimertinib after chemoradiation for EGFR-mutated stage III; PACIFIC-2 concurrent durvalumab negative","note":"Unresectable stage III non-small-cell lung cancer","from":"stage-iii-unresectable-nsclc","refs":["laura","osimertinib","durvalumab"]},{"group":"history","date":"2024","precision":"year","title":"Lifileucel: first approved cell therapy for a solid tumour","note":"Advanced melanoma (unresectable stage III and stage IV)","from":"advanced-melanoma","refs":["lifileucel","c-144-01"]},{"group":"history","date":"2024","precision":"year","title":"Lifileucel: first TIL therapy","note":"Melanoma","from":"melanoma","refs":["lifileucel"]},{"group":"history","date":"2024","precision":"year","title":"LUMINOSITY: telisotuzumab vedotin response rate 35 percent in c-Met high tumours","note":"MET exon 14 and MET-amplified non-small-cell lung cancer","from":"met-altered-nsclc","refs":["luminosity","telisotuzumab-vedotin"]},{"group":"history","date":"2024","precision":"year","title":"Lymphocyte-rich stage I tumours do well without chemotherapy","note":"Triple-negative breast cancer (TNBC). Leon-Ferre and colleagues, 1,966 untreated patients: five-year distant recurrence-free survival 94 percent with lymphocytes of 50 percent or m...","from":"tnbc","refs":["paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024","tils","idea-tnbc-de-escalation-for-exceptional-responders"]},{"group":"history","date":"2024","precision":"year","title":"MARIPOSA: amivantamab plus lazertinib approved first line; LAURA: osimertinib after chemoradiation in stage III","note":"EGFR-mutated non-small-cell lung cancer","from":"egfr-mutant-nsclc","refs":["mariposa","amivantamab-plus-lazertinib","laura","cho-byoung-chul"]},{"group":"history","date":"2024","precision":"year","title":"MARS 2 ends radical surgery as standard","note":"Pleural mesothelioma","from":"pleural-mesothelioma","refs":["mars-2"]},{"group":"history","date":"2024","precision":"year","title":"MARS 2: surgery worsens survival; pembrolizumab-chemotherapy approved (September)","note":"Mesothelioma","from":"mesothelioma","refs":["mars-2","pembrolizumab"]},{"group":"history","date":"2024","precision":"year","title":"MOTION phase 3 positive for vimseltinib","note":"Tenosynovial giant cell tumour (TGCT). Gelderblom and colleagues, Lancet.","from":"tenosynovial-giant-cell-tumour","refs":["vimseltinib","motion"]},{"group":"history","date":"2024","precision":"year","title":"NADINA neoadjuvant phase 3; lifileucel first TIL therapy; KEYNOTE-006 ten-year data; COMBI-AD ten-year data","note":"Melanoma","from":"melanoma","refs":["nadina","lifileucel","c-144-01","keynote-006"]},{"group":"history","date":"2024","precision":"year","title":"NADINA: neoadjuvant ipilimumab plus nivolumab cuts events by two thirds","note":"Stage III melanoma (after surgery)","from":"stage-iii-melanoma","refs":["nadina"]},{"group":"history","date":"2024","precision":"year","title":"NALIRIFOX approved; zenocutuzumab for NRG1 fusions","note":"Pancreatic ductal adenocarcinoma","from":"pancreatic","refs":["nalirifox","zenocutuzumab"]},{"group":"history","date":"2024","precision":"year","title":"NETTER-2: first-line lutetium-177 dotatate in grade 2 to 3 disease; CABINET pancreatic cohort published","note":"Pancreatic neuroendocrine tumours","from":"pancreatic-net","refs":["nct03972488","lutathera","cabinet"]},{"group":"history","date":"2024","precision":"year","title":"NETTER-2: first-line lutetium-177 dotatate in grade 2 to 3 tumours with Ki-67 up to 55 percent","note":"Grade 3 well-differentiated neuroendocrine tumour","from":"grade-3-net","refs":["nct03972488","lutathera"]},{"group":"history","date":"2024","precision":"year","title":"NETTER-2: first-line PRRT","note":"Neuroendocrine tumours","from":"neuroendocrine","refs":[]},{"group":"history","date":"2024","precision":"year","title":"NETTER-2: lutetium-177 dotatate first line for grade 2 to 3 tumours; CABINET published","note":"Small intestinal neuroendocrine tumours","from":"small-intestinal-net","refs":["nct03972488","lutathera","cabinet"]},{"group":"history","date":"2024","precision":"year","title":"NETTER-2: PRRT first line in grade 2-3; CABINET published; AlphaMedix Breakthrough designation","note":"Neuroendocrine tumours","from":"neuroendocrine","refs":["lutathera","cabinet","alphamedix"]},{"group":"history","date":"2024","precision":"year","title":"NIAGARA: perioperative durvalumab improves survival","note":"Muscle-invasive and advanced bladder cancer","from":"muscle-invasive-bladder-cancer","refs":["niagara"]},{"group":"history","date":"2024","precision":"year","title":"Nogapendekin alfa inbakicept with BCG approved","note":"Non-muscle-invasive bladder cancer","from":"non-muscle-invasive-bladder-cancer","refs":["nogapendekin-alfa"]},{"group":"history","date":"2024","precision":"year","title":"NORPACT-1: neoadjuvant FOLFIRINOX does not lengthen survival in clearly resectable disease","note":"Resectable pancreatic ductal adenocarcinoma","from":"resectable-pdac","refs":["folfirinox"]},{"group":"history","date":"2024","precision":"year","title":"PACE-B: five-fraction stereotactic radiotherapy non-inferior at five years","note":"Localised prostate cancer, very low and low risk","from":"prostate-low-risk","refs":["pace-b"]},{"group":"history","date":"2024","precision":"year","title":"PACE-B: stereotactic radiotherapy in five fractions non-inferior","note":"Localised prostate cancer, intermediate risk","from":"prostate-intermediate-risk","refs":["pace-b"]},{"group":"history","date":"2024","precision":"year","title":"Pembrolizumab and dostarlimab approved with chemotherapy for all comers","note":"Advanced or recurrent endometrial cancer","from":"advanced-recurrent-endometrial-cancer","refs":["pembrolizumab","dostarlimab"]},{"group":"history","date":"2024","precision":"year","title":"Pembrolizumab approved with chemoradiation (Jan); tisotumab full approval (Apr); FDA approves HPV self-collection (May); COMPASSION-16 published; SHAPE trial su...","note":"Cervical cancer","from":"cervical","refs":["keynote-a18","tisotumab-vedotin","hpv-testing","compassion-16"]},{"group":"history","date":"2024","precision":"year","title":"Pembrolizumab approved with chemoradiation for high-risk locally advanced disease","note":"Locally advanced cervical cancer","from":"locally-advanced-cervical-cancer","refs":["pembrolizumab"]},{"group":"history","date":"2024","precision":"year","title":"Pembrolizumab with chemotherapy approved","note":"Pleural mesothelioma","from":"pleural-mesothelioma","refs":["keynote-483"]},{"group":"history","date":"2024","precision":"year","title":"PERSEUS quadruplet approved; FDA accepts MRD as an endpoint; DREAMM-7/8 positive; cilta-cel and ide-cel approved after 1-2 lines","note":"Multiple myeloma","from":"multiple-myeloma","refs":["perseus","mrd-negativity-myeloma","dreamm-7","dreamm-8"]},{"group":"history","date":"2024","precision":"year","title":"PERSEUS: daratumumab-VRd around transplant approved as standard induction","note":"Newly diagnosed multiple myeloma, transplant-eligible","from":"myeloma-transplant-eligible","refs":["perseus","daratumumab"]},{"group":"history","date":"2024","precision":"year","title":"PhALLCON: ponatinib beats imatinib in adults with Ph-positive ALL","note":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)","from":"all-paediatric-ph-positive","refs":["phallcon","ponatinib"]},{"group":"history","date":"2024","precision":"year","title":"PHERGain chemotherapy omission; DESTINY-Breast12 brain metastases; zanidatamab approved (BTC)","note":"HER2-positive breast cancer","from":"breast-her2-positive","refs":["phergain","destiny-breast12","zanidatamab"]},{"group":"history","date":"2024","precision":"year","title":"PHERGain: PET-guided omission of chemotherapy","note":"Early HER2-positive breast cancer","from":"her2-positive-early-breast-cancer","refs":["phergain"]},{"group":"history","date":"2024","precision":"year","title":"POD1UM-303: retifanlimab + chemotherapy improves PFS/OS","note":"Anal cancer (squamous cell carcinoma). FDA approval 2025.","from":"anal","refs":["retifanlimab"]},{"group":"history","date":"2024","precision":"year","title":"Pooled ONC201 phase 2 data","note":"Diffuse midline glioma, H3 K27-altered (including DIPG). Durable objective responses in recurrent H3 K27M DMG reported in JCO; ACTION phase 3 open.","from":"dipg-dmg","refs":["dordaviprone","action-dmg"]},{"group":"history","date":"2024","precision":"year","title":"PREOPANC-2: neoadjuvant FOLFIRINOX and gemcitabine chemoradiation give similar survival","note":"Borderline resectable pancreatic ductal adenocarcinoma","from":"borderline-resectable-pdac","refs":["preopanc","folfirinox"]},{"group":"history","date":"2024","precision":"year","title":"Randomised trial: no benefit of systemic chemotherapy in low-grade mucinous carcinoma peritonei","note":"Appendiceal cancer and pseudomyxoma peritonei","from":"appendiceal","refs":["folfox"]},{"group":"history","date":"2024","precision":"year","title":"Repotrectinib gains tumour-agnostic accelerated approval for NTRK fusions","note":"NTRK fusion-positive non-small-cell lung cancer","from":"ntrk-fusion-nsclc","refs":["repotrectinib","nct03093116"]},{"group":"history","date":"2024","precision":"year","title":"Revumenib approved for relapsed KMT2A-rearranged acute leukaemia after AUGMENT-101","note":"Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)","from":"all-infant","refs":["revumenib","augment-101"]},{"group":"history","date":"2024","precision":"year","title":"Revumenib approved for relapsed KMT2A-rearranged acute leukaemia from the age of one","note":"Acute myeloid leukaemia in children","from":"aml-paediatric","refs":["revumenib","augment-101"]},{"group":"history","date":"2024","precision":"year","title":"Revumenib: first menin inhibitor","note":"Acute myeloid leukaemia","from":"aml","refs":["revumenib"]},{"group":"history","date":"2024","precision":"year","title":"Revumenib: first menin inhibitor; magrolimab fails","note":"Acute myeloid leukaemia. Approved for KMT2A-rearranged acute leukaemia (AUGMENT-101). Magrolimab (CD47) discontinued after ENHANCE trials, a setback for TP53-mutated AML.","from":"aml","refs":["revumenib","augment-101","magrolimab"]},{"group":"history","date":"2024","precision":"year","title":"SHAPE: simple hysterectomy non-inferior to radical hysterectomy in low-risk early disease","note":"Early cervical cancer and fertility-sparing surgery","from":"early-cervical-cancer","refs":[]},{"group":"history","date":"2024","precision":"year","title":"Shield blood test approved for screening; BREAKWATER accelerated approval; CheckMate 8HW","note":"Colorectal cancer","from":"colorectal","refs":["shield","breakwater","checkmate-8hw"]},{"group":"history","date":"2024","precision":"year","title":"SPLASH: second PSMA radioligand improves rPFS but not OS","note":"Prostate cancer","from":"prostate","refs":["splash","lu177-psma-it"]},{"group":"history","date":"2024","precision":"year","title":"STARGLO shows OS benefit for glofitamab-GemOx; odronextamab approved in EU","note":"Diffuse large B-cell lymphoma","from":"dlbcl","refs":["starglo","odronextamab"]},{"group":"history","date":"2024","precision":"year","title":"SU2C-SARC032: pembrolizumab plus preoperative radiotherapy improves disease-free survival","note":"Undifferentiated pleomorphic sarcoma (UPS)","from":"undifferentiated-pleomorphic-sarcoma","refs":["pembrolizumab","imrt-igrt"]},{"group":"history","date":"2024","precision":"year","title":"SWOG S1826 (nivolumab-AVD) and HD21 (BrECADD) published; nivolumab-AVD becomes the preferred regimen","note":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","from":"advanced-stage-classical-hodgkin-lymphoma","refs":["swog-s1826","hd21","nivolumab","brentuximab-vedotin"]},{"group":"history","date":"2024","precision":"year","title":"Tarlatamab accelerated approval after DeLLphi-301","note":"Extensive-stage small-cell lung cancer","from":"extensive-stage-sclc","refs":["tarlatamab","paper-dellphi-301-nejm-2023","amgen"]},{"group":"history","date":"2024","precision":"year","title":"Tarlatamab accelerated approval; ADRIATIC changes limited-stage care","note":"Small-cell lung cancer","from":"sclc","refs":["tarlatamab","adriatic"]},{"group":"history","date":"2024","precision":"year","title":"Tarlatamab approved for small-cell lung cancer, opening DLL3 as a target for extrapulmonary carcinoma","note":"Extrapulmonary neuroendocrine carcinoma","from":"extrapulmonary-nec","refs":["tarlatamab","dll3"]},{"group":"history","date":"2024","precision":"year","title":"Tarlatamab shows activity against DLL3-positive neuroendocrine prostate cancer","note":"Neuroendocrine and small-cell prostate cancer","from":"prostate-nepc","refs":["tarlatamab","dll3"]},{"group":"history","date":"2024","precision":"year","title":"Tarlatamab: first targeted drug for small-cell lung cancer","note":"Lung cancer (all types)","from":"lung-cancer","refs":["tarlatamab"]},{"group":"history","date":"2024","precision":"year","title":"The first prospective immunotherapy evidence in transplant recipients","note":"Cutaneous squamous cell carcinoma. Twelve kidney transplant recipients given cemiplimab after cross-taper to a mammalian target of rapamycin inhibitor with pulsed steroids: no reje...","from":"cutaneous-scc","refs":["cemiplimab-kidney-transplant-cscc"]},{"group":"history","date":"2024","precision":"year","title":"The first real signal in microsatellite-stable disease","note":"Colorectal cancer. An Fc-enhanced CTLA-4 antibody with a PD-1 antibody gave 17% responses and 61% disease control in 101 evaluable heavily pre-treated microsatellite-stable patient...","from":"colorectal","refs":["paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024"]},{"group":"history","date":"2024","precision":"year","title":"The UK breast reporting dataset is rewritten","note":"Breast cancer (all types). RCPath G148 version 3 (November 2024) adds the ER low positive category, a separate section on male breast disease, updated handling of specimens after n...","from":"breast-cancer","refs":["er-pr-scoring-breast","er-pr-negative-threshold"]},{"group":"history","date":"2024","precision":"year","title":"Tislelizumab approved in the US (second-line ESCC, first-line gastric); ESOPEC favours FLOT over CROSS in adenocarcinoma","note":"Oesophageal cancer","from":"esophageal","refs":["tislelizumab","flot"]},{"group":"history","date":"2024","precision":"year","title":"Tisotumab vedotin full approval; COMPASSION-16 positive for cadonilimab in China","note":"Recurrent or metastatic cervical cancer","from":"recurrent-metastatic-cervical-cancer","refs":["tisotumab-vedotin","compassion-16"]},{"group":"history","date":"2024","precision":"year","title":"Tovorafenib approved for relapsed BRAF-altered pLGG","note":"Paediatric low-grade glioma. FIREFLY-1 (Nature Medicine 2024) shows durable responses across fusions and V600E; FDA accelerated approval April 2024.","from":"paediatric-low-grade-glioma","refs":["tovorafenib","firefly-1"]},{"group":"history","date":"2024","precision":"year","title":"Trastuzumab deruxtecan approved for HER2 3+ solid tumours after DESTINY-PanTumor02","note":"p53-abnormal endometrial cancer, including uterine serous carcinoma","from":"endometrial-p53-abnormal","refs":["trastuzumab-deruxtecan","destiny-pantumor02"]},{"group":"history","date":"2024","precision":"year","title":"Trastuzumab deruxtecan receives tumour-agnostic approval for HER2-positive solid tumours","note":"Advanced and metastatic small bowel adenocarcinoma","from":"advanced-small-bowel-adenocarcinoma","refs":["trastuzumab-deruxtecan"]},{"group":"history","date":"2024","precision":"year","title":"TRIANGLE and ECHO","note":"Mantle cell lymphoma. Ibrutinib replaces transplant in fit patients; acalabrutinib + BR improves PFS first line in older patients.","from":"mantle-cell-lymphoma","refs":["ibrutinib","acalabrutinib"]},{"group":"history","date":"2024","precision":"year","title":"TrilynX (xevinapant) stopped for futility; petosemtamab Breakthrough designation","note":"Head and neck squamous cell carcinoma","from":"head-and-neck","refs":["trilynx","petosemtamab"]},{"group":"history","date":"2024","precision":"year","title":"TrilynX stopped: xevinapant worsens outcomes","note":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","from":"hpv-negative-head-and-neck-cancer","refs":["trilynx"]},{"group":"history","date":"2024","precision":"year","title":"Tumour-agnostic approval of trastuzumab deruxtecan for HER2 3+ solid tumours after DESTINY-CRC02","note":"HER2-amplified colorectal cancer","from":"her2-amplified-colorectal","refs":["trastuzumab-deruxtecan","destiny-crc02"]},{"group":"history","date":"2024","precision":"year","title":"Tunlametinib approved in China for NRAS-mutant melanoma","note":"Mucosal melanoma","from":"mucosal-melanoma","refs":["tunlametinib"]},{"group":"history","date":"2024","precision":"year","title":"Tunlametinib approved in China for NRAS-mutant melanoma","note":"Acral melanoma","from":"acral-melanoma","refs":["tunlametinib"]},{"group":"history","date":"2024","precision":"year","title":"Universal germline testing recommended","note":"Triple-negative breast cancer (TNBC). ASCO-SSO recommends BRCA1/2 testing for all breast cancer diagnosed at 65 or under and for every PARP inhibitor candidate.","from":"tnbc","refs":["paper-bedrosian-asco-sso-germline-testing-breast-jco-2024","brca-germline"]},{"group":"history","date":"2024","precision":"year","title":"VERONA: venetoclax plus azacitidine does not lengthen life","note":"Higher-risk myelodysplastic syndromes","from":"mds-higher-risk","refs":["venetoclax","azacitidine"]},{"group":"history","date":"2024","precision":"year","title":"Vorasidenib approved","note":"Glioma & glioblastoma","from":"glioblastoma","refs":["vorasidenib"]},{"group":"history","date":"2024","precision":"year","title":"Vorasidenib approved for IDH-mutant glioma","note":"Brain and spinal cord tumours (all types). First targeted drug for grade 2 astrocytoma and oligodendroglioma after surgery (INDIGO trial).","from":"brain-tumours","refs":["vorasidenib"]},{"group":"history","date":"2024","precision":"year","title":"Zanidatamab for HER2-positive biliary cancer","note":"Gallbladder cancer. FDA accelerated approval (November 2024) on HERIZON-BTC-01, in which gallbladder cancer was the largest subgroup.","from":"gallbladder","refs":["zanidatamab","her2"]},{"group":"history","date":"2024","precision":"year","title":"Zanidatamab for HER2+ BTC","note":"Biliary tract cancer (cholangiocarcinoma)","from":"cholangiocarcinoma","refs":["zanidatamab"]},{"group":"history","date":"2024","precision":"year","title":"Zanidatamab receives accelerated approval for HER2-positive biliary tract cancer","note":"Extrahepatic cholangiocarcinoma (perihilar and distal)","from":"extrahepatic-cholangiocarcinoma","refs":["zanidatamab","her2"]},{"group":"history","date":"2024","precision":"year","title":"Zanidatamab: first HER2 approval in biliary cancer; T-DXd tumour-agnostic HER2 IHC3+; NALIRICC negative","note":"Biliary tract cancer (cholangiocarcinoma)","from":"cholangiocarcinoma","refs":["zanidatamab","trastuzumab-deruxtecan","naliricc"]},{"group":"history","date":"2024","precision":"year","title":"Zenocutuzumab approved for NRG1 fusion-positive pancreatic cancer","note":"Metastatic pancreatic ductal adenocarcinoma","from":"metastatic-pdac","refs":["zenocutuzumab"]},{"group":"history","date":"2024","precision":"year","title":"Zenocutuzumab approved for NRG1 fusion-positive pancreatic cancer","note":"KRAS wild-type pancreatic ductal adenocarcinoma","from":"kras-wild-type-pdac","refs":["zenocutuzumab"]},{"group":"history","date":"2024","precision":"year","title":"Zolbetuximab approved (Japan March, US October); zanidatamab approved in biliary cancer","note":"Gastric & gastro-oesophageal junction cancer","from":"gastric","refs":["zolbetuximab","zanidatamab"]},{"group":"history","date":"2024","precision":"year","title":"Zolbetuximab approved for claudin 18.2-positive disease","note":"Oesophageal and junctional adenocarcinoma","from":"oesophageal-adenocarcinoma","refs":["zolbetuximab"]},{"group":"history","date":"2024","precision":"year","title":"Zolbetuximab approved in Japan, the United States and Europe","note":"Claudin 18.2-positive gastric cancer","from":"gastric-cldn18-2-positive","refs":["zolbetuximab"]},{"group":"history","date":"2024","precision":"year","title":"Zolbetuximab: first CLDN18.2 drug","note":"Gastric & gastro-oesophageal junction cancer","from":"gastric","refs":[]},{"group":"law","date":"2024","precision":"year","title":"BIOSECURE Act","note":"United States, statute.","from":"biosecure-act","refs":[]},{"group":"law","date":"2024","precision":"year","title":"FDA laboratory-developed test (LDT) rule","note":"United States, regulation.","from":"fda-ldt-rule","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"[ 89 Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","note":"Shuch B, Pantuck AJ, Bernhard JC, et al. The Lancet Oncology.","from":"paper-shuch-lancet-oncol","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"177 Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prosta...","note":"Morris MJ, Castellano D, Herrmann K, et al. The Lancet.","from":"paper-psmafore-lancet-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"3-year invasive disease-free survival with chemotherapy de-escalation using an 18 F-FDG-PET-based, pathological complete response-adapted strategy in HER2-posit...","note":"Pérez-García JM, Cortés J, Ruiz-Borrego M, et al. The Lancet.","from":"paper-phergain-lancet-2024-update","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening","note":"Chung DC, Gray DM, Singh H, et al. New England Journal of Medicine.","from":"paper-eclipse-shield-n-engl-j-med-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"A foundation model for clinical-grade computational pathology and rare cancers detection","note":"Vorontsov E, Bozkurt A, Casson A, et al. Nature Medicine.","from":"paper-vorontsov-nat-med","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"A pathology foundation model for cancer diagnosis and prognosis prediction","note":"Wang X, Zhao J, Marostica E, et al. Nature.","from":"paper-wang-nature","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma","note":"Tang XX, Shimada H, Ikegaki N. Current oncology.","from":"paper-cd47-neuroblastoma-curr-oncol-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"A visual-language foundation model for computational pathology","note":"Lu MY, Chen B, Williamson DFK, et al. Nature Medicine.","from":"paper-lu-nat-med","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"A whole-slide foundation model for digital pathology from real-world data","note":"Xu H, Usuyama N, Bagga J, et al. Nature.","from":"paper-xu-nature","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","note":"Abramson J, Adler J, Dunger J, et al. Nature.","from":"paper-abramson-nature","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Surviv...","note":"Loibl S, Jassem J, Sonnenblick A, et al. Journal of Clinical Oncology.","from":"paper-aphinity-j-clin-oncol-2024-update","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer","note":"Cheng Y, Spigel DR, Cho BC, et al. New England Journal of Medicine.","from":"paper-adriatic-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Alectinib in resected ALK-positive non-small-cell lung cancer","note":"Wu YL, Dziadziuszko R, Ahn JS, et al. New England Journal of Medicine.","from":"paper-wu-alina-adjuvant-alectinib-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","note":"Besse B, Pons-Tostivint E, Park K, et al. Nature Medicine.","from":"paper-nct03334617-nat-med-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","note":"Bullock AJ, Schlechter BL, Fakih MG, et al. Nature Medicine.","from":"paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Bray 2024: GLOBOCAN 2022, the world's cancer count for 36 cancers in 185 countries","note":"Bray F, Laversanne M, Sung H, et al. CA: A Cancer Journal for Clinicians.","from":"paper-bray-globocan-2022-cacancer-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (S...","note":"Oliveira M, Pominchuk D, Nowecki Z, et al. The Lancet Oncology.","from":"paper-nct04214288-lancet-oncol-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Cancer incidence and mortality in China, 2022","note":"Han B, Zheng R, Zeng H, et al. Journal of the National Cancer Center.","from":"paper-han-j-natl-cancer-cent","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline","note":"Braun IM, Bohlke K, Abrams DI, et al. Journal of Clinical Oncology.","from":"paper-braun-j-clin-oncol","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Capivasertib: First Approval","note":"Shirley M. Drugs.","from":"paper-capivasertib-breast-hr-positive-drugs-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial","note":"Wolf J, Hochmair M, Han JY, et al. The Lancet Oncology.","from":"paper-geometry-mono-1-lancet-oncol-2024-update","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Clinical and genomic characterization of ERBB2-altered gallbladder cancer: exploring differences between an American and a Chilean cohort","note":"Mondaca S, Walch H, Sepulveda S, et al. JCO Global Oncology.","from":"paper-mondaca-erbb2-gallbladder-us-chile-jco-go-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal canc...","note":"Segal NH, Tie J, Kopetz S, et al. British Journal of Cancer.","from":"paper-nct04068610-br-j-cancer-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study","note":"Perez JK, Kleber J, Rothe M, et al. JCO Precision Oncology.","from":"paper-perez-jco-precis-oncol","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","note":"Holderfield M, Lee BJ, Jiang J, et al. Nature.","from":"paper-holderfield-ras-on-multi-selective-inhibitor-nature-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"CONTINUUM: induction-concurrent chemoradiotherapy with or without sintilimab in locoregionally advanced nasopharyngeal carcinoma","note":"Liu X, Zhang Y, Yang KY, et al. The Lancet.","from":"paper-continuum-sintilimab-nasopharyngeal-liu-lancet-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"CUPISCO: molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary","note":"Krämer A, Bochtler T, Pauli C, et al. The Lancet.","from":"paper-cupisco-molecularly-guided-therapy-cup-lancet-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","note":"Bardia A, Hu X, Dent R, et al. New England Journal of Medicine.","from":"paper-destiny-breast06-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"DESTINY-PanTumor02: trastuzumab deruxtecan in HER2-expressing solid tumours","note":"Meric-Bernstam F, Makker V, Oaknin A, et al. Journal of Clinical Oncology.","from":"paper-destiny-pantumor02-jco-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pan...","note":"Philip PA, Sahai V, Bahary N, et al. Journal of Clinical Oncology.","from":"paper-philip-j-clin-oncol","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer","note":"Westin SN, Moore K, Chon HS, et al. Journal of Clinical Oncology.","from":"paper-duo-e-jco-2023","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001","note":"Wirth LJ, Brose MS, Subbiah V, et al. Journal of Clinical Oncology.","from":"paper-nct03157128-j-clin-oncol-2024-update","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised ph...","note":"Oh DY, He AR, Bouattour M, et al. The lancet. Gastroenterology & hepatology.","from":"paper-topaz-1-lancet-gastroenterol-hepatol-2024-update","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","note":"Loibl S, André F, Bachelot T, et al. Annals of Oncology.","from":"paper-esmo-early-breast-cancer-guideline-ann-oncol-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission","note":"Litzow MR, Sun Z, Mattison RJ, et al. New England Journal of Medicine.","from":"paper-e1910-blinatumomab-mrd-negative-all-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study","note":"Zhou Q, Meng X, Sun L, et al. Journal of Thoracic Oncology.","from":"paper-zhou-j-thorac-oncol","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study","note":"Li W, Xiong A, Yang N, et al. Journal of Clinical Oncology.","from":"paper-nct04395677-j-clin-oncol-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Mu...","note":"Zager JS, Orloff M, Ferrucci PF, et al. Annals of surgical oncology.","from":"paper-zager-ann-surg-oncol","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial","note":"Li C, Zhou K, Hu Y, et al. JAMA Oncology.","from":"paper-li-jama-oncol","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer","note":"Powles T, Valderrama BP, Gupta S, et al. New England Journal of Medicine.","from":"paper-ev-302-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Exposures to bleach, peroxide, disinfectants, antimalarials, and ivermectin reported to the California Poison Control System before and during the COVID-19 pand...","note":"Ghai A, Sabour E, Salonga R, Ho R, Apollonio DE. Public Health Reports.","from":"paper-ghai-california-poison-control-ivermectin-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma","note":"Natrajan K, Kaushal M, George B, et al. Clinical Cancer Research.","from":"paper-ciltacabtagene-autoleucel-multiple-myeloma-clin-cancer-res-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"First Safety and Efficacy Data with the Radiohybrid 177 Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer","note":"Dierks A, Gäble A, Rinscheid A, et al. Journal of Nuclear Medicine.","from":"paper-nct05413850-j-nucl-med-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD...","note":"Dudnichenko O, Penkov K, McKean M, et al. European Journal of Cancer.","from":"paper-nct04657991-eur-j-cancer-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial","note":"Wang ZX, Peng J, Liang X, et al. Med (New York, N.Y.).","from":"paper-nct04547166-med-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"FIRSTMAPPP: sunitinib for metastatic progressive phaeochromocytomas and paragangliomas","note":"Baudin E, Goichot B, Berruti A, et al. The Lancet.","from":"paper-firstmappp-sunitinib-metastatic-ppgl-baudin-lancet-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Foresight-a generative pretrained transformer for modelling of patient timelines using electronic health records: a retrospective modelling study","note":"Kraljevic Z, Bean D, Shek A, et al. The Lancet Digital Health.","from":"paper-kraljevic-lancet-digit-health","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Gallbladder cancer mortality in Chile: has the government program targeting young gallstone patients had an impact?","note":"Cid V, Vargas C, Delgado I, et al. American Journal of Epidemiology.","from":"paper-cid-chile-programme-gallbladder-cancer-mortality-am-j-epidemiol-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Gallbladder Cancer: Is It Time to Modify the Explicit Health Guarantees (GES) Program?","note":"Samaniego CP, de Aretxabala X, Castillo F, et al. Revista Medica de Chile.","from":"paper-samaniego-chile-ges-programme-evaluation-rev-med-chile-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline","note":"Bedrosian I, Somerfield MR, Achatz MI, et al. Journal of Clinical Oncology.","from":"paper-bedrosian-asco-sso-germline-testing-breast-jco-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"GHSG HD21: PET-guided BrECADD versus escalated BEACOPP in advanced-stage classical Hodgkin lymphoma","note":"Borchmann P, Ferdinandus J, Schneider G, et al. The Lancet.","from":"paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Canc...","note":"Martín M, Lim E, Chavez-MacGregor M, et al. Journal of Clinical Oncology.","from":"paper-nct04576455-j-clin-oncol-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3...","note":"Abramson JS, Ku M, Hertzberg M, et al. The Lancet.","from":"paper-glofitamab-dlbcl-lancet-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"IELSG37: omission of radiotherapy in primary mediastinal B-cell lymphoma after a negative PET scan","note":"Martelli M, Ceriani L, Ciccone G, et al. Journal of Clinical Oncology.","from":"paper-ielsg37-pmbcl-martelli-jco-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed","note":"Platzbecker U, Santini V, Fenaux P, et al. The Lancet.","from":"paper-imerge-imetelstat-mds-lancet-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer","note":"Turner NC, Im SA, Saura C, et al. New England Journal of Medicine.","from":"paper-inavo120-n-engl-j-med-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial","note":"Mukohara T, Park YH, Sommerhalder D, et al. Nature Medicine.","from":"paper-nct04606446-nat-med-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Initial clinical experience with [ 177 Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy fro...","note":"Hansen AR, Probst S, Beauregard JM, et al. Frontiers in oncology.","from":"paper-splash-front-oncol-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"innovaTV 301: tisotumab vedotin versus chemotherapy as second- or third-line therapy for recurrent cervical cancer","note":"Vergote I, González-Martín A, Fujiwara K, et al. New England Journal of Medicine.","from":"paper-innovatv-301-tisotumab-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"INTERLACE: induction chemotherapy before chemoradiotherapy for locally advanced cervical cancer","note":"McCormack M, Eminowicz G, Gallardo D, et al. The Lancet.","from":"paper-interlace-lancet-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"International Anal Neoplasia Society consensus guidelines for anal cancer screening","note":"Stier EA, Clarke MA, Deshmukh AA, et al. International Journal of Cancer.","from":"paper-ians-anal-cancer-screening-guidelines-ijc-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas (2024)","note":"Ohtsuka T, Fernandez-Del Castillo C, Furukawa T, et al. Pancreatology.","from":"paper-kyoto-2024-evidence-based-guidelines-ipmn-pancreatology-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"INTUITT-NF2: brigatinib in NF2-related schwannomatosis with progressive tumours","note":"Plotkin SR, Yohay KH, Nghiemphu PL, et al. New England Journal of Medicine.","from":"paper-intuitt-nf2-brigatinib-plotkin-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial","note":"HARMONi-A Study Investigators, Fang W, Zhao Y, et al. JAMA.","from":"paper-harmoni-a-jama-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery","note":"Weber JS, Carlino MS, Khattak A, et al. The Lancet.","from":"paper-keynote-942-lancet-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (overall survival)","note":"Lorusso D, Xiang Y, Hasegawa K, et al. The Lancet.","from":"paper-keynote-a18-os-lancet-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival)","note":"Lorusso D, Xiang Y, Hasegawa K, et al. The Lancet.","from":"paper-keynote-a18-pfs-lancet-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127","note":"Montoya S, Bourcier J, Noviski M, et al. Science.","from":"paper-montoya-science","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Large-scale foundation model on single-cell transcriptomics","note":"Hao M, Gong J, Zeng X, et al. Nature methods.","from":"paper-hao-nat-methods","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","note":"Brown CE, Hibbard JC, Alizadeh D, et al. Nature Medicine.","from":"paper-brown-nat-med","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial","note":"Walls GM, Mistry H, Barlesi F, et al. International Journal of Radiation Oncology, Biology, Physics.","from":"paper-convert-int-j-radiat-oncol-biol-phys-2024-update","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial","note":"Verheij FS, Omer DM, Williams H, et al. Journal of Clinical Oncology.","from":"paper-opra-j-clin-oncol-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)","note":"Kozono D, Hua X, Wu MC, et al. Journal of Thoracic Oncology.","from":"paper-kozono-j-thorac-oncol","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","note":"Pant S, Wainberg ZA, Weekes CD, et al. Nature Medicine.","from":"paper-pant-nat-med","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","note":"Cho BC, Lu S, Felip E, et al. New England Journal of Medicine.","from":"paper-mariposa-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"MARS 2: extended pleurectomy decortication plus chemotherapy versus chemotherapy alone for pleural mesothelioma","note":"Lim E, Waller D, Lau K, et al. The Lancet Respiratory Medicine.","from":"paper-mars-2-lancet-respir-med-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD acute myeloid leukaemia","note":"Levis MJ, Hamadani M, Logan B, et al. Journal of Clinical Oncology.","from":"paper-morpho-gilteritinib-levis-jco-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"MYC targeting by OMO-103 in solid tumors: a phase 1 trial","note":"Garralda E, Beaulieu ME, Moreno V, et al. Nature Medicine.","from":"paper-garralda-nat-med","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"NADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma","note":"Blank CU, Lucas MW, Scolyer RA, et al. New England Journal of Medicine.","from":"paper-nadina-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma prev...","note":"Vogel A, Saborowski A, Wenzel P, et al. The lancet. Gastroenterology & hepatology.","from":"paper-naliricc-lancet-gastroenterol-hepatol-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","note":"Slamon D, Lipatov O, Nowecki Z, et al. New England Journal of Medicine.","from":"paper-natalee-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","note":"Singh S, Halperin D, Myrehaug S, et al. The Lancet.","from":"paper-netter-2-lancet-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening","note":"Imperiale TF, Porter K, Zella J, et al. New England Journal of Medicine.","from":"paper-blue-c-n-engl-j-med-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer","note":"Powles T, Catto JWF, Galsky MD, et al. New England Journal of Medicine.","from":"paper-niagara-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","note":"Chalabi M, Verschoor YL, Tan PB, et al. New England Journal of Medicine.","from":"paper-niche-2-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer (CheckMate 8HW)","note":"André T, Elez E, Van Cutsem E, et al. New England Journal of Medicine.","from":"paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"NORPACT-1: neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer","note":"Labori KJ, Bratlie SO, Andersson B, et al. The Lancet Gastroenterology and Hepatology.","from":"paper-norpact-1-neoadjuvant-folfirinox-labori-lancet-gastroenterol-hepatol-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma","note":"Arrillaga-Romany I, Gardner SL, Odia Y, et al. Journal of Clinical Oncology.","from":"paper-arrillaga-romany-j-clin-oncol","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","note":"Lu S, Kato T, Dong X, et al. New England Journal of Medicine.","from":"paper-lu-laura-osimertinib-stage-iii-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Overall survival with [ 177 Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, o...","note":"Hofman MS, Emmett L, Sandhu S, et al. The Lancet Oncology.","from":"paper-therap-lancet-oncol-2024-update","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","note":"Schmid P, Cortes J, Dent R, et al. New England Journal of Medicine.","from":"paper-keynote-522-n-engl-j-med-2024-update","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Palliative Care for Patients With Cancer: ASCO Guideline Update","note":"Sanders JJ, Temin S, Ghoshal A, et al. Journal of Clinical Oncology.","from":"paper-sanders-j-clin-oncol","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"PARTIQoL: phase 3 randomised trial of proton therapy versus IMRT for localised prostate cancer (ASTRO 2024 late-breaking abstract)","note":"Efstathiou JA, Yeap BY, Michalski JM, et al. International Journal of Radiation Oncology, Biology, Physics.","from":"paper-partiqol-astro-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Perioperative Nivolumab in Resectable Lung Cancer","note":"Cascone T, Awad MM, Spicer JD, et al. New England Journal of Medicine.","from":"paper-nct04025879-n-engl-j-med-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"PERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma","note":"Sonneveld P, Dimopoulos MA, Boccadoro M, et al. New England Journal of Medicine.","from":"paper-perseus-dara-vrd-transplant-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer","note":"van As N, Griffin C, Tree A, et al. New England Journal of Medicine.","from":"paper-van-as-n-engl-j-med","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"PHOCUS: an oncolytic vaccinia virus before sorafenib in liver cancer did worse than sorafenib alone","note":"Abou-Alfa GK, Galle PR, Chao Y, et al. Liver Cancer.","from":"paper-abou-alfa-phocus-pexa-vec-liver-cancer-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Ponsegromab for the Treatment of Cancer Cachexia","note":"Groarke JD, Crawford J, Collins SM, et al. New England Journal of Medicine.","from":"paper-groarke-ponsegromab-cancer-cachexia-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Predicting transcriptional outcomes of novel multigene perturbations with GEARS","note":"Roohani Y, Huang K, Leskovec J. Nature Biotechnology.","from":"paper-roohani-nat-biotechnol","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors","note":"Naito Y, Nakamura S, Kawaguchi-Sakita N, et al. International journal of clinical oncology.","from":"paper-nct05101096-int-j-clin-oncol-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial","note":"Martin RM, Turner EL, Young GJ, et al. JAMA.","from":"paper-martin-jama","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind...","note":"Zeidan AM, Ando K, Rauzy O, et al. The Lancet Haematology.","from":"paper-zeidan-lancet-haematol","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"scGPT: toward building a foundation model for single-cell multi-omics using generative AI","note":"Cui H, Wang C, Maan H, et al. Nature methods.","from":"paper-cui-nat-methods","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Segment anything in medical images","note":"Ma J, He Y, Li F, et al. Nature Communications.","from":"paper-ma-nat-commun","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Severe drug-induced liver injury due to self-administration of the veterinary anthelmintic medication fenbendazole","note":"Thakurdesai A, Rivera-Matos L, Nagra N, Busch B, Mais DD, Cave MC. ACG Case Reports Journal.","from":"paper-thakurdesai-fenbendazole-liver-injury-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"SHAPE: simple versus radical hysterectomy in low-risk early cervical cancer","note":"Plante M, Kwon JS, Ferguson S, et al. New England Journal of Medicine.","from":"paper-shape-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Siegel 2024: Cancer statistics, 2024, the American Cancer Society's annual US report","note":"Siegel RL, Giaquinto AN, Jemal A. CA: A Cancer Journal for Clinicians.","from":"paper-siegel-cancer-statistics-2024-cacancer-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","note":"D'Angelo SP, Araujo DM, Abdul Razak AR, et al. The Lancet.","from":"paper-spearhead-1-lancet-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-K...","note":"Wang M, Fan Y, Sun M, et al. The Lancet. Respiratory medicine.","from":"paper-nct05712902-lancet-respir-med-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults","note":"Herrera AF, LeBlanc M, Castellino SM, et al. New England Journal of Medicine.","from":"paper-swog-s1826-nivolumab-avd-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer","note":"Fizazi K, Bernard-Tessier A, Roubaud G, et al. NEJM Evidence.","from":"paper-nct03436485-nejm-evid-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Telehealth vs In-Person Early Palliative Care for Patients With Advanced Lung Cancer: A Multisite Randomized Clinical Trial","note":"Greer JA, Temel JS, El-Jawahri A, et al. JAMA.","from":"paper-greer-jama","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cance...","note":"Camidge DR, Bar J, Horinouchi H, et al. Journal of Clinical Oncology.","from":"paper-luminosity-j-clin-oncol-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treat...","note":"Martínez-Cibrián N, Ortiz-Maldonado V, Español-Rego M, et al. British journal of haematology.","from":"paper-martinez-cibrian-br-j-haematol","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"The self-experiment: a virologist treated her own recurrent breast cancer with two viruses she made in her own laboratory","note":"Forcic D, Mrsic K, Peric-Balja M, Kurtovic T, Ramic S, Silovski T, Pedisic I, Milas I, Halassy B. Vaccines.","from":"paper-halassy-self-experiment-ovt-vaccines-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","note":"Kilburn LB, Khuong-Quang DA, Hansford JR, et al. Nature Medicine.","from":"paper-kilburn-nat-med","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the U...","note":"Slater S, Bryant A, Aresu M, et al. Clinical Cancer Research.","from":"paper-tracc-clin-cancer-res-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Towards a general-purpose foundation model for computational pathology","note":"Chen RJ, Ding T, Lu MY, et al. Nature Medicine.","from":"paper-chen-nat-med","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian can...","note":"Zhu M, Madia P, Crawford A, et al. Clinical and translational science.","from":"paper-zhu-clin-transl-sci","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial","note":"Harbeck N, Ciruelos E, Jerusalem G, et al. Nature Medicine.","from":"paper-destiny-breast12-nat-med-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial","note":"Ohba A, Morizane C, Kawamoto Y, et al. Journal of Clinical Oncology.","from":"paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","note":"Raghav K, Siena S, Takashima A, et al. The Lancet Oncology.","from":"paper-destiny-crc02-lancet-oncol-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","note":"Li BT, Meric-Bernstam F, Bardia A, et al. The Lancet Oncology.","from":"paper-nct04639219-lancet-oncol-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"TRIANGLE: ibrutinib with immunochemotherapy with or without autologous transplant versus immunochemotherapy and transplant in untreated mantle cell lymphoma","note":"Dreyling M, Doorduijn J, Giné E, et al. The Lancet.","from":"paper-triangle-ibrutinib-mantle-cell-lymphoma-dreyling-lancet-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"TRIDENT-1: repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","note":"Drilon A, Camidge DR, Lin JJ, et al. New England Journal of Medicine.","from":"paper-trident-1-repotrectinib-nejm-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survi...","note":"Bardia A, Jhaveri K, Im SA, et al. Journal of Clinical Oncology.","from":"paper-tropion-breast01-jco-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer","note":"Leon-Ferre RA, Jonas SF, Salgado R, et al. JAMA.","from":"paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial","note":"Zhou I, Plana D, Palmer AC. Clinical Cancer Research.","from":"paper-zhou-clin-cancer-res","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses","note":"Lane MM, Gamage E, Du S, et al. BMJ.","from":"paper-lane-bmj","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","note":"Gelderblom H, Bhadri V, Stacchiotti S, et al. The Lancet.","from":"paper-gelderblom-lancet","refs":[]},{"group":"paper","date":"2024","precision":"year","title":"Zevorcabtagene Autoleucel: First Approval","note":"Dhillon S. Molecular diagnosis & therapy.","from":"paper-dhillon-mol-diagn-ther","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-different...","note":"Lancet","from":"simron-singh","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2...","note":"Lancet Oncology","from":"louise-emmett","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostat...","note":"Lancet","from":"michael-morris","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"2024 ESC Guidelines for the management of peripheral arterial and aortic diseases","note":"European Heart Journal","from":"daniel-staub","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"A phase I trial of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid cancers","note":"Cancer Discovery","from":"nina-bhardwaj","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3","note":"Annals of Oncology","from":"matthew-goetz","refs":["xavier-pivot"]},{"group":"person-paper","date":"2024","precision":"year","title":"Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour re...","note":"The Lancet Oncology","from":"pierre-vera","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1)","note":"Lancet","from":"sandra-dangelo","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC","note":"New England Journal of Medicine","from":"lu-shun","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC (MARIPOSA)","note":"NEJM","from":"lee-dae-ho","refs":["cho-byoung-chul"]},{"group":"person-paper","date":"2024","precision":"year","title":"An unconventional case study of neoadjuvant oncolytic virotherapy for recurrent breast cancer","note":"Vaccines","from":"beata-halassy","refs":["dubravko-forcic"]},{"group":"person-paper","date":"2024","precision":"year","title":"Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib","note":"Cancers","from":"ruben-mesa","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, p...","note":"Lancet","from":"peter-borchmann","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","note":"New England Journal of Medicine","from":"toni-choueiri","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Belzutifan versus everolimus for advanced renal-cell carcinoma (LITESPARK-005)","note":"NEJM","from":"laurence-albiges","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults","note":"New England Journal of Medicine","from":"mark-litzow","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion","note":"Nature Communications","from":"pier-giuseppe-pelicci","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Cancer education and training within the South Asian Association for Regional Cooperation (SAARC) countries","note":"The Lancet Oncology","from":"mostafa-aziz-sumon","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Cancer research in South Asian Association for Regional Cooperation (SAARC) countries","note":"The Lancet Oncology","from":"mostafa-aziz-sumon","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Capivasertib and fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291)","note":"Lancet Oncology","from":"mafalda-oliveira","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors","note":"Cancer Immunology, Immunotherapy","from":"xia-michelle","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Clinical Validation of Digital Healthcare Solutions: State of the Art, Challenges and Opportunities","note":"Healthcare","from":"adria-comella-carnice","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma (PERSEUS)","note":"NEJM","from":"pieter-sonneveld","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Defining national research priorities for prostate cancer in Zambia: using the Delphi process for comprehensive cancer policy setting in sub-Saharan Africa","note":"BMJ Oncology","from":"susan-msadabwe","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Design and implementation of a humanitarian cancer care programme for Ukrainian refugees in Moldova and Romania","note":"Lancet Oncol","from":"ruslan-baltaga","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Development of a clinical prediction score for perioperative complications following metastatic spinal surgery (PERCOM) score","note":"Heliyon","from":"yasuharu-nakashima","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2...","note":"Clinical and Translational Radiation Oncology","from":"maximilian-niyazi","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","note":"Journal of Clinical Oncology","from":"funda-meric-bernstam","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer (EV-302)","note":"NEJM","from":"lee-jae-lyun","refs":["thomas-powles"]},{"group":"person-paper","date":"2024","precision":"year","title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","note":"New England Journal of Medicine","from":"shilpa-gupta","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","note":"Annals of Oncology","from":"anna-fagotti","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Establishing conditions for the generation and maintenance of estrogen receptor-positive organoid models of breast cancer","note":"Breast Cancer Research","from":"senthil-muthuswamy","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EU...","note":"European Journal of Surgical Oncology","from":"isabel-rubio","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2)","note":"Lancet Respiratory Medicine","from":"dean-fennell","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","note":"Annals of Oncology","from":"bruno-sangro","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Fractionated radiotherapy for spinal tumors: A literature review regarding spinal glioma, ependymoma, and meningioma","note":"Neuro-Oncology Advances","from":"maximilian-niyazi","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors","note":"Nature Communications","from":"joaquin-arribas","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer","note":"npj Precision Oncology","from":"naoto-ueno","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","note":"CA: A Cancer Journal for Clinicians","from":"bray-freddie","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Glofitamab plus gemcitabine and oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma (STARGLO)","note":"Lancet","from":"michael-dickinson","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a...","note":"Lancet Haematology","from":"benjamin-kasenda","refs":["elisabeth-schorb"]},{"group":"person-paper","date":"2024","precision":"year","title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantati...","note":"Lancet","from":"martin-dreyling","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL (FLAIR)","note":"NEJM","from":"peter-hillmen","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer (INAVO120)","note":"NEJM","from":"komal-jhaveri","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Incidence of De Novo Post-Transplant Malignancies in Thai Adult Kidney Transplant Recipients: A Single-Center, Population-Controlled, Retrospective Cohort Study...","note":"Transplant International","from":"atiporn-ingsathit","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working...","note":"The Lancet Haematology","from":"ruben-mesa","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942)","note":"Lancet","from":"jeffrey-weber","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG IN...","note":"Lancet","from":"mary-mccormack","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Intratumoral antigen signaling traps CD8 + T cells to confine exhaustion to the tumor site","note":"Science Immunology","from":"ken-smith","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","note":"NEJM","from":"marcela-maus","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant (HARMONi-A)","note":"JAMA","from":"qing-zhou","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Ivonescimab plus chemotherapy in NSCLC with EGFR variant after EGFR-TKI: the HARMONi-A phase 3 randomized clinical trial","note":"JAMA","from":"fang-wenfeng","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer","note":"The Lancet","from":"giovanni-scambia","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study","note":"Journal of Clinical Oncology","from":"steven-le-gouill","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive NSCLC: 5-year outcomes from CROWN","note":"Journal of Clinical Oncology","from":"solomon-benjamin","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Microbial and Metabolic Gut Profiling across Seven Malignancies Identifies Fecal Faecalibacillus intestinalis and Formic Acid as Commonly Altered in Cancer Pati...","note":"International Journal of Molecular Sciences","from":"michal-mikula","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Multi-ancestry GWAS meta-analyses of lung cancer reveal susceptibility loci and elucidate smoking-independent genetic risk","note":"Nature Communications","from":"rachel-ramoni","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer","note":"Journal of Thoracic Oncology","from":"karen-kelly","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Neoadjuvant chemotherapy with cisplatin plus 5-FU vs docetaxel, cisplatin, and 5-FU vs chemoradiotherapy for oesophageal squamous cell carcinoma (JCOG1109 NExT)","note":"Lancet","from":"kitagawa-yuko","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer (NICHE-2)","note":"NEJM","from":"myriam-chalabi","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma (NADINA)","note":"NEJM","from":"christian-blank","refs":["georgina-long"]},{"group":"person-paper","date":"2024","precision":"year","title":"Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial","note":"Nature Medicine","from":"martin-schuler","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China","note":"Lung Cancer","from":"li-weimin","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"NICHE-2: a single dose of ipilimumab and two of nivolumab before surgery clears dMMR colon cancer in most patients","note":"New England Journal of Medicine","from":"myriam-chalabi","refs":["ton-schumacher"]},{"group":"person-paper","date":"2024","precision":"year","title":"Nivolumab plus AVD in advanced-stage classic Hodgkin's lymphoma (SWOG S1826)","note":"NEJM","from":"kara-kelly","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma","note":"New England Journal of Medicine","from":"alex-herrera","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma","note":"Blood","from":"steven-le-gouill","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival","note":"Journal for ImmunoTherapy of Cancer","from":"robert-martuza","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Open vs minimally invasive radical hysterectomy in early cervical cancer: LACC trial final analysis","note":"JCO","from":"pedro-ramirez","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe","note":"Acta Oncologica","from":"kjetil-tasken","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx1...","note":"Lancet","from":"domenica-lorusso","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer (NIAGARA)","note":"NEJM","from":"thomas-powles","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Perioperative nivolumab in resectable lung cancer (CheckMate 77T)","note":"NEJM","from":"tina-cascone","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors","note":"Journal for ImmunoTherapy of Cancer","from":"xia-michelle","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Gro...","note":"Ann Oncol","from":"nicola-normanno","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (...","note":"Lancet Haematology","from":"martin-bornhauser","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","note":"New England Journal of Medicine","from":"alexander-drilon","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in metastatic hormone-sensitive prostate cancer (UpFrontPSMA)","note":"Lancet Oncology","from":"sandhu-shahneen","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Small cell lung cancer and neuroendocrine tumours","note":"Breathe (Sheff)","from":"assia-konsoulova","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation","note":"American Society of Clinical Oncology Educational Book","from":"chee-cheng-ean","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial","note":"Lancet Oncology","from":"shankar-siva","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development","note":"Cancers","from":"shivaani-kummar","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study","note":"Cancer Research Communications","from":"naoto-ueno","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"TGFβ in Pancreas and Colorectal Cancer: Opportunities to Overcome Therapeutic Resistance","note":"Clinical Cancer Research","from":"boris-pasche","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"The Crucial Role of Patient Advocates in Pediatric Oncology Research—Insights From ACCELERATE","note":"JAMA Pediatrics","from":"nicole-scobie","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"The Lancet Breast Cancer Commission","note":"Lancet","from":"charlotte-coles","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer","note":"Nature","from":"jean-abraham","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer (innovaTV 301)","note":"NEJM","from":"ignace-vergote","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Towards a general-purpose foundation model for computational pathology (UNI)","note":"Nature Medicine","from":"faisal-mahmood","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Transfusions of packed red blood cells in surgery for liver cancer: predictor of impaired overall survival but not recurrence-free survival – impact of blood tr...","note":"Journal of Gastrointestinal Surgery","from":"jurgen-weitz","refs":[]},{"group":"person-paper","date":"2024","precision":"year","title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","note":"Nature Medicine","from":"yonemori-kan","refs":[]},{"group":"regulatory","date":"2024","precision":"year","title":"Brenetafusp: designation (US)","note":"Phase 3 PRISM-MEL-301 initiated after FDA alignment on design","from":"brenetafusp","refs":[]},{"group":"regulatory","date":"2024","precision":"year","title":"Petosemtamab: designation (US)","note":"Breakthrough Therapy designation for HNSCC","from":"petosemtamab","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"AlphaFold 3","note":"First use in humans or first approval, as the technology record states it.","from":"alphafold3","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"Boltz-1 / Boltz-2 (MIT, open)","note":"First use in humans or first approval, as the technology record states it.","from":"boltz","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"Cell-free DNA methylation tests","note":"First use in humans or first approval, as the technology record states it.","from":"cfdna-methylation-testing","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"CellFM","note":"First use in humans or first approval, as the technology record states it.","from":"cellfm","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"Chai-1 / Chai-2","note":"First use in humans or first approval, as the technology record states it.","from":"chai-1","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"CHIEF (Harvard, Yu Lab)","note":"First use in humans or first approval, as the technology record states it.","from":"chief","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"ESM3 (EvolutionaryScale)","note":"First use in humans or first approval, as the technology record states it.","from":"esm3","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"Foresight (generative EHR model)","note":"First use in humans or first approval, as the technology record states it.","from":"foresight-ehr","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"H-optimus (Bioptimus)","note":"First use in humans or first approval, as the technology record states it.","from":"h-optimus","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"Hibou (HistAI)","note":"First use in humans or first approval, as the technology record states it.","from":"hibou","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"In vivo CAR-T","note":"First use in humans or first approval, as the technology record states it.","from":"in-vivo-car-t","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"Med-Gemini and MedLM (Google)","note":"First use in humans or first approval, as the technology record states it.","from":"med-gemini","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"MedSAM / SAM-Med3D (segment anything for medicine)","note":"First use in humans or first approval, as the technology record states it.","from":"medsam","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"Menin inhibitors","note":"First use in humans or first approval, as the technology record states it.","from":"menin-inhibitors","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"Merlin (Stanford abdominal CT vision-language model)","note":"First use in humans or first approval, as the technology record states it.","from":"merlin-ct","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"Multitarget stool RNA test (ColoSense)","note":"First use in humans or first approval, as the technology record states it.","from":"multitarget-stool-rna-test","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"Nicheformer (spatial single-cell)","note":"First use in humans or first approval, as the technology record states it.","from":"nicheformer","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"Nucleotide Transformer (InstaDeep)","note":"First use in humans or first approval, as the technology record states it.","from":"nucleotide-transformer","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"Phenom-2 and Recursion OS","note":"First use in humans or first approval, as the technology record states it.","from":"phenom-2","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"PLUTO (PathAI)","note":"First use in humans or first approval, as the technology record states it.","from":"pluto","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"Prov-GigaPath (Microsoft, Providence)","note":"First use in humans or first approval, as the technology record states it.","from":"prov-gigapath","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"scFoundation (BioMap)","note":"First use in humans or first approval, as the technology record states it.","from":"scfoundation","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"scGPT","note":"First use in humans or first approval, as the technology record states it.","from":"scgpt","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"TCR-T cell therapy","note":"First use in humans or first approval, as the technology record states it.","from":"tcr-t","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"TIL therapy","note":"First use in humans or first approval, as the technology record states it.","from":"til-therapy","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"TITAN (whole-slide multimodal model)","note":"First use in humans or first approval, as the technology record states it.","from":"titan","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"UNI and CONCH (Harvard, Mahmood Lab)","note":"First use in humans or first approval, as the technology record states it.","from":"uni-conch","refs":[]},{"group":"technology","date":"2024","precision":"year","title":"Virchow / Virchow2 (Paige, MSK)","note":"First use in humans or first approval, as the technology record states it.","from":"virchow","refs":[]},{"group":"trial","date":"2024","precision":"year","title":"A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer reported","from":"nct05243550","refs":["urothelial","non-muscle-invasive-bladder-cancer"]},{"group":"trial","date":"2024","precision":"year","title":"A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC reported","from":"nct05246514","refs":["nsclc","sclc","her2-mutant-nsclc","trastuzumab-deruxtecan"]},{"group":"trial","date":"2024","precision":"year","title":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC reported","from":"nct04606771","refs":["nsclc","sclc","met-altered-nsclc","osimertinib"]},{"group":"trial","date":"2024","precision":"year","title":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) reported","from":"nct04489771","refs":["rcc","belzutifan"]},{"group":"trial","date":"2024","precision":"year","title":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Sma...","from":"nct04538664","refs":["nsclc","egfr-mutant-nsclc","amivantamab","pemetrexed"]},{"group":"trial","date":"2024","precision":"year","title":"A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy reported","from":"nct04023526","refs":["aml","azacitidine","cusatuzumab"]},{"group":"trial","date":"2024","precision":"year","title":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolu...","note":"Eighteen-month event-free survival 70.2 percent with perioperative nivolumab against 50.0 percent with chemotherapy alone (hazard ratio 0.58, 97.36 percent confidence interval 0.42...","from":"nct04025879","refs":["nsclc","resectable-nsclc","nivolumab","carboplatin"]},{"group":"trial","date":"2024","precision":"year","title":"A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanc...","from":"nct04172597","refs":["breast-cancer","colorectal","poziotinib"]},{"group":"trial","date":"2024","precision":"year","title":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements reported","note":"Repotrectinib produced responses in 79 percent of ROS1 inhibitor-naive patients (median progression-free survival 35.7 months) and 38 percent after one ROS1 inhibitor, including 59...","from":"nct03093116","refs":["metastatic-cancer","ros1-positive-nsclc","ntrk-fusion-nsclc","repotrectinib"]},{"group":"trial","date":"2024","precision":"year","title":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib reported","from":"nct03673501","refs":["gist","gist-imatinib-resistant","ripretinib","sunitinib"]},{"group":"trial","date":"2024","precision":"year","title":"A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations reported","from":"nct04639219","refs":["melanoma","trastuzumab-deruxtecan"]},{"group":"trial","date":"2024","precision":"year","title":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metasta...","from":"nct04721977","refs":["metastatic-cancer","tucatinib","trastuzumab","capecitabine"]},{"group":"trial","date":"2024","precision":"year","title":"A-BRAVE reported","note":"Primary DFS endpoint not met (figures not indexed); exploratory: avelumab benefit only with baseline TILs 30% or more (stratum B 3-year DDFS 92.0% vs 58.7%, HR 0.20; interaction p...","from":"a-brave","refs":["tnbc","tnbc-early","avelumab"]},{"group":"trial","date":"2024","precision":"year","title":"Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer reported","from":"nct02788981","refs":["breast-cancer","mifepristone","paclitaxel"]},{"group":"trial","date":"2024","precision":"year","title":"ACE-Breast-02 reported","note":"PFS 11.3 vs 8.2 months, HR 0.64.","from":"ace-breast-02","refs":["breast-her2-positive","arx788","lapatinib"]},{"group":"trial","date":"2024","precision":"year","title":"ADRIATIC reported","note":"OS 55.9 vs 33.4 months, HR 0.73.","from":"adriatic","refs":["sclc","limited-stage-sclc","durvalumab"]},{"group":"trial","date":"2024","precision":"year","title":"AMPLIFY reported","note":"3-year PFS 76.5% (AV) / 83.1% (AVO) vs 66.5%.","from":"amplify","refs":["cll","cll-treatment-naive","acalabrutinib","venetoclax"]},{"group":"trial","date":"2024","precision":"year","title":"AQUILA reported","note":"Subcutaneous daratumumab delayed progression to active myeloma or death compared with active monitoring in high-risk smouldering myeloma; approved in the United States in 2025.","from":"aquila","refs":["smouldering-myeloma","multiple-myeloma","daratumumab"]},{"group":"trial","date":"2024","precision":"year","title":"ARANOTE reported","note":"Darolutamide plus androgen deprivation lengthened radiographic progression-free survival compared with androgen deprivation alone; approved for this use in 2025.","from":"aranote","refs":["prostate-mhspc","prostate","darolutamide"]},{"group":"trial","date":"2024","precision":"year","title":"AUGMENT-101 reported","note":"CR+CRh 22.8%, ORR 63.2% in KMT2Ar cohort.","from":"augment-101","refs":["aml","all-leukemia","aml-npm1-kmt2a","revumenib"]},{"group":"trial","date":"2024","precision":"year","title":"AVENGER 500 reported","note":"No overall survival benefit from adding devimistat to modified FOLFIRINOX.","from":"avenger-500","refs":["pancreatic","devimistat","folfirinox"]},{"group":"trial","date":"2024","precision":"year","title":"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations reported","from":"nct04579380","refs":["endometrial","cervical","cholangiocarcinoma","nsclc"]},{"group":"trial","date":"2024","precision":"year","title":"BEAT-meso (ETOP 13-18) reported","note":"OS not significantly improved overall; benefit in non-epithelioid subgroup.","from":"beat-meso","refs":["mesothelioma","atezolizumab","pemetrexed"]},{"group":"trial","date":"2024","precision":"year","title":"BLUE-C reported","note":"Sensitivity 93.9% for colorectal cancer (FIT 67.3%); specificity 90.6% for advanced neoplasia.","from":"blue-c","refs":["colorectal","cologuard-plus"]},{"group":"trial","date":"2024","precision":"year","title":"BOND-003 reported","note":"CR 75.2%; 24-month CR 41.8%.","from":"bond-003","refs":["urothelial","cretostimogene"]},{"group":"trial","date":"2024","precision":"year","title":"BRUIN CLL-321 reported","note":"PFS 11.2 vs 8.7 months; HR 0.58.","from":"bruin-cll-321","refs":["cll","cll-relapsed","pirtobrutinib"]},{"group":"trial","date":"2024","precision":"year","title":"CABINET (Alliance A021602) reported","note":"PFS HR 0.23 (pNET), 0.38 (epNET).","from":"cabinet","refs":["neuroendocrine","pancreatic-net","small-intestinal-net","lung-net"]},{"group":"trial","date":"2024","precision":"year","title":"Cemiplimab for kidney transplant recipients with advanced skin squamous cell carcinoma reported","note":"No kidney rejection or graft loss in 12 kidney transplant recipients given cemiplimab after cross-taper to a mammalian target of rapamycin inhibitor with pulsed corticosteroids, wi...","from":"cemiplimab-kidney-transplant-cscc","refs":["cutaneous-scc","advanced-cutaneous-scc","skin-cancer","cemiplimab"]},{"group":"trial","date":"2024","precision":"year","title":"CEPHEUS reported","note":"MRD-neg 60.9% vs 39.4%; PFS HR 0.57.","from":"cepheus","refs":["multiple-myeloma","myeloma-transplant-ineligible","daratumumab","bortezomib"]},{"group":"trial","date":"2024","precision":"year","title":"CheckMate 8HW reported","note":"First-line PFS 54.1 vs 5.9 months (HR 0.21); combination vs nivolumab PFS HR 0.62.","from":"checkmate-8hw","refs":["colorectal","msi-high-colorectal","nivolumab","ipilimumab"]},{"group":"trial","date":"2024","precision":"year","title":"CheckMate 9DW reported","note":"OS 23.7 vs 20.6 months, HR 0.79; ORR 36% vs 13%.","from":"checkmate-9dw","refs":["hcc","hcc-advanced","nivolumab","ipilimumab"]},{"group":"trial","date":"2024","precision":"year","title":"CLL12 reported","note":"Ibrutinib delayed progression to symptomatic disease but did not improve survival: five-year overall survival 93.3 percent against 93.6 percent with placebo; watch and wait remains...","from":"cll12","refs":["cll","cll-treatment-naive","leukaemia","ibrutinib"]},{"group":"trial","date":"2024","precision":"year","title":"COG AALL1731 reported","note":"3-year DFS 96.0% vs 87.9%; HR 0.39.","from":"aall1731","refs":["all-leukemia","all-paediatric-standard-risk","blinatumomab","crisantaspase"]},{"group":"trial","date":"2024","precision":"year","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations reported","from":"nct02883049","refs":["all-leukemia","leukaemia","clofarabine","cyclophosphamide"]},{"group":"trial","date":"2024","precision":"year","title":"COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) reported","note":"At two years the rate of ipsilateral invasive cancer with active monitoring was non-inferior to guideline-concordant surgery.","from":"comet-dcis","refs":["ductal-carcinoma-in-situ","breast-cancer","tamoxifen","letrozole"]},{"group":"trial","date":"2024","precision":"year","title":"COMPASSION-16 / AK104-303 reported","note":"OS HR 0.64; PFS HR 0.62.","from":"compassion-16","refs":["cervical","recurrent-metastatic-cervical-cancer","cadonilimab","bevacizumab"]},{"group":"trial","date":"2024","precision":"year","title":"CONTINUUM reported","note":"Three-year event-free survival 86 percent with sintilimab added to chemoradiotherapy against 76 percent without (hazard ratio 0.59, p 0.019); grade 3 to 4 adverse events 74 against...","from":"continuum","refs":["locoregionally-advanced-nasopharyngeal-carcinoma","nasopharyngeal","sintilimab","gemcitabine"]},{"group":"trial","date":"2024","precision":"year","title":"CROSSFIRE reported","note":"Median overall survival 16.1 months with MRI-guided stereotactic ablative radiotherapy against 12.5 months with irreversible electroporation (hazard ratio 1.39, 95 percent confiden...","from":"crossfire","refs":["pancreatic","locally-advanced-pdac","folfirinox"]},{"group":"trial","date":"2024","precision":"year","title":"CUPISCO reported","note":"Median progression-free survival 6.1 months with molecularly guided therapy versus 4.4 months with continued chemotherapy (hazard ratio 0.72); overall survival immature.","from":"cupisco","refs":["cancer-of-unknown-primary","cup-unfavourable","atezolizumab","alectinib"]},{"group":"trial","date":"2024","precision":"year","title":"DESTINY-Breast06 reported","note":"PFS HR 0.62.","from":"destiny-breast06","refs":["breast-hr-positive","her2-low-metastatic-breast-cancer","hr-positive-metastatic-post-cdk46","trastuzumab-deruxtecan"]},{"group":"trial","date":"2024","precision":"year","title":"DESTINY-Breast12 reported","note":"CNS ORR 71.7%; 12-month PFS 61.6% in brain-metastasis cohort.","from":"destiny-breast12","refs":["breast-her2-positive","secondary-brain-tumours","her2-positive-breast-brain-metastases","trastuzumab-deruxtecan"]},{"group":"trial","date":"2024","precision":"year","title":"DREAMM-7 reported","note":"PFS 36.6 vs 13.4 months, HR 0.41; OS HR 0.58.","from":"dreamm-7","refs":["multiple-myeloma","myeloma-relapsed-refractory","belantamab-mafodotin","bortezomib"]},{"group":"trial","date":"2024","precision":"year","title":"DREAMM-8 reported","note":"PFS HR 0.52.","from":"dreamm-8","refs":["multiple-myeloma","myeloma-relapsed-refractory","belantamab-mafodotin"]},{"group":"trial","date":"2024","precision":"year","title":"Durvalumab and Tremelimumab for Pediatric Malignancies reported","from":"nct03837899","refs":["childhood-cancers","durvalumab","tremelimumab"]},{"group":"trial","date":"2024","precision":"year","title":"ECLIPSE (Shield blood test) reported","note":"Sensitivity 83.1% for colorectal cancer, 13.2% for advanced precancerous lesions; specificity 89.6%.","from":"eclipse-shield","refs":["colorectal","shield"]},{"group":"trial","date":"2024","precision":"year","title":"ECOG-ACRIN E1910 reported","note":"3-year OS 85% vs 68%; HR 0.41.","from":"e1910","refs":["all-leukemia","aya-cancers","blinatumomab"]},{"group":"trial","date":"2024","precision":"year","title":"EMBER-3 reported","note":"PFS HR 0.62 (ESR1-mutant, monotherapy); HR 0.57 (combination vs monotherapy).","from":"ember-3","refs":["breast-hr-positive","hr-positive-metastatic-post-cdk46","imlunestrant","abemaciclib"]},{"group":"trial","date":"2024","precision":"year","title":"EMERALD-1 reported","note":"PFS HR 0.77; OS HR 0.80, not significant.","from":"emerald-1","refs":["hcc","hcc-intermediate","durvalumab"]},{"group":"trial","date":"2024","precision":"year","title":"ESOPEC reported","note":"Perioperative FLOT improved overall survival compared with CROSS chemoradiotherapy in resectable oesophageal adenocarcinoma.","from":"esopec","refs":["oesophageal-adenocarcinoma","esophageal","fluorouracil","leucovorin"]},{"group":"trial","date":"2024","precision":"year","title":"FELIX reported","note":"ORR 77%, CR 55%; grade ≥3 CRS 2.4%.","from":"felix","refs":["all-leukemia","obecabtagene-autoleucel"]},{"group":"trial","date":"2024","precision":"year","title":"FIRSTMAPPP reported","note":"Progression-free survival at 12 months 36 percent with sunitinib against 19 percent with placebo, meeting the primary endpoint of the first randomised trial in the disease.","from":"firstmappp","refs":["metastatic-ppgl","pheochromocytoma-paraganglioma","sunitinib"]},{"group":"trial","date":"2024","precision":"year","title":"FOCUS reported","note":"Objective response rate 36.3% by independent central review in 91 treated patients (complete response 7.7%), above the prespecified historical benchmark; median duration of respons...","from":"nct02678572","refs":["uveal-melanoma","hepzato","melphalan"]},{"group":"trial","date":"2024","precision":"year","title":"FUMANBA-1 reported","note":"ORR about 96% in infused patients (JAMA Oncol 2024).","from":"fumanba-1","refs":["multiple-myeloma","equecabtagene-autoleucel"]},{"group":"trial","date":"2024","precision":"year","title":"GBM AGILE reported","note":"Regorafenib, the first arm, did not improve overall survival in newly diagnosed or recurrent glioblastoma; paxalisib and VAL-083 did not graduate; later arms continue.","from":"gbm-agile","refs":["glioblastoma","brain-tumours","regorafenib","temozolomide"]},{"group":"trial","date":"2024","precision":"year","title":"GHSG HD21 reported","note":"4-year PFS 94.3% vs 90.9%, HR 0.66; less toxicity.","from":"hd21","refs":["hodgkin-lymphoma","advanced-stage-classical-hodgkin-lymphoma","brentuximab-vedotin","doxorubicin"]},{"group":"trial","date":"2024","precision":"year","title":"HARMONi-2 reported","note":"PFS HR 0.51; OS statistically significant (2026 announcement).","from":"harmoni-2","refs":["nsclc","pdl1-high-nsclc","ivonescimab","pembrolizumab"]},{"group":"trial","date":"2024","precision":"year","title":"HARMONi-A reported","note":"PFS 7.1 vs 4.8 months, HR 0.46.","from":"harmoni-a","refs":["nsclc","ivonescimab","pemetrexed","carboplatin"]},{"group":"trial","date":"2024","precision":"year","title":"HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer reported","from":"nct04619004","refs":["nsclc","sclc","egfr-mutant-nsclc","patritumab-deruxtecan"]},{"group":"trial","date":"2024","precision":"year","title":"I-SPY 2.2 reported","note":"Ongoing; the first block results and de-escalation rates were reported from 2024.","from":"i-spy-2-2","refs":["breast-cancer","tnbc","breast-her2-positive","breast-hr-positive"]},{"group":"trial","date":"2024","precision":"year","title":"IELSG37 reported","note":"30-month progression-free survival 96.7% (observation) vs 98.5% (radiotherapy) in patients with complete metabolic response; radiotherapy can be omitted.","from":"ielsg37","refs":["primary-mediastinal-b-cell-lymphoma","rituximab"]},{"group":"trial","date":"2024","precision":"year","title":"IGNYTE-ESO reported","note":"ORR 42%.","from":"ignyte-eso","refs":["sarcoma","letetresgene-autoleucel"]},{"group":"trial","date":"2024","precision":"year","title":"IMROZ reported","note":"PFS HR 0.60.","from":"imroz","refs":["multiple-myeloma","myeloma-transplant-ineligible","isatuximab","bortezomib"]},{"group":"trial","date":"2024","precision":"year","title":"INTUITT-NF2 reported","note":"Brigatinib produced radiographic responses in 10 percent of target tumours and 23 percent of all tumours, slowed growth of every tumour type and improved hearing in 35 percent of e...","from":"intuitt-nf2","refs":["vestibular-schwannoma","meningioma","brain-tumours","brigatinib"]},{"group":"trial","date":"2024","precision":"year","title":"IPATunity130 reported","note":"PFS 7.4 vs 6.1 months (HR 1.02, 0.71 to 1.45); OS 24.4 vs 24.9 months (HR 1.08). Negative.","from":"ipatunity130","refs":["tnbc","tnbc-metastatic","ipatasertib","paclitaxel"]},{"group":"trial","date":"2024","precision":"year","title":"KRYSTAL-12 reported","note":"PFS HR 0.58.","from":"krystal-12","refs":["nsclc","kras-g12c-nsclc","adagrasib"]},{"group":"trial","date":"2024","precision":"year","title":"LAPIS reported","note":"Primary overall survival endpoint not met.","from":"lapis-trial","refs":["pancreatic","pamrevlumab","gemcitabine-nab-paclitaxel","folfirinox"]},{"group":"trial","date":"2024","precision":"year","title":"LAURA reported","note":"PFS HR 0.16.","from":"laura","refs":["nsclc","egfr-mutant-nsclc","stage-iii-unresectable-nsclc","osimertinib"]},{"group":"trial","date":"2024","precision":"year","title":"LEAP-012 reported","note":"PFS HR 0.66; final OS HR 0.98.","from":"leap-012","refs":["hcc","hcc-intermediate","lenvatinib","pembrolizumab"]},{"group":"trial","date":"2024","precision":"year","title":"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma reported","from":"nct02159066","refs":["melanoma","infigratinib","capmatinib"]},{"group":"trial","date":"2024","precision":"year","title":"LINKER-MM1 reported","note":"ORR 70%, ≥CR 45%.","from":"linker-mm1","refs":["multiple-myeloma","myeloma-relapsed-refractory","linvoseltamab"]},{"group":"trial","date":"2024","precision":"year","title":"LUMINOSITY reported","note":"ORR 28.6% overall; 34.6% in c-Met high, 22.9% in c-Met intermediate.","from":"luminosity","refs":["nsclc","met-altered-nsclc","telisotuzumab-vedotin"]},{"group":"trial","date":"2024","precision":"year","title":"LUMMICAR STUDY 1 reported","from":"lummicar-1","refs":["multiple-myeloma","zevorcabtagene-autoleucel"]},{"group":"trial","date":"2024","precision":"year","title":"Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) reported","from":"nct04313881","refs":["mds","magrolimab","azacitidine"]},{"group":"trial","date":"2024","precision":"year","title":"MANIFEST-2 reported","note":"Pelabresib plus ruxolitinib roughly doubled the week-24 spleen volume response over ruxolitinib alone; the symptom endpoint did not reach significance.","from":"manifest-2","refs":["primary-myelofibrosis","myeloproliferative-neoplasms","pelabresib","ruxolitinib"]},{"group":"trial","date":"2024","precision":"year","title":"MARS 2 reported","note":"OS HR 1.28 favouring no surgery; median 19.3 vs 24.8 months.","from":"mars-2","refs":["mesothelioma","pleural-mesothelioma"]},{"group":"trial","date":"2024","precision":"year","title":"MERMAID-2 reported","from":"mermaid-2","refs":["nsclc","durvalumab"]},{"group":"trial","date":"2024","precision":"year","title":"MORPHO reported","note":"Relapse-free survival hazard ratio 0.679 for gilteritinib against placebo, not statistically significant overall; in the prespecified MRD-positive half of patients the hazard ratio...","from":"morpho","refs":["aml-flt3","aml","leukaemia","gilteritinib"]},{"group":"trial","date":"2024","precision":"year","title":"MOTION reported","note":"ORR 40% vs 0%.","from":"motion","refs":["sarcoma","tenosynovial-giant-cell-tumour","vimseltinib"]},{"group":"trial","date":"2024","precision":"year","title":"NADINA reported","note":"12-month EFS 83.7% vs 57.2%; HR 0.32.","from":"nadina","refs":["melanoma","stage-iii-melanoma","nivolumab","ipilimumab"]},{"group":"trial","date":"2024","precision":"year","title":"NALIRICC (AIO) reported","note":"OS 6.9 vs 8.2 months; not improved.","from":"naliricc","refs":["cholangiocarcinoma","gallbladder","biliary-tract-cancer","liposomal-irinotecan"]},{"group":"trial","date":"2024","precision":"year","title":"NeoPACT reported","note":"pCR 58% (48 to 67); RCB 0 or 1 69%; 3-year EFS 86% (98% with pCR, 68% without).","from":"neopact","refs":["tnbc","tnbc-early","carboplatin","docetaxel"]},{"group":"trial","date":"2024","precision":"year","title":"Neotorch reported","note":"Median event-free survival not estimable against 15.1 months in stage III disease (hazard ratio 0.40, 95 percent confidence interval 0.28 to 0.57).","from":"neotorch","refs":["resectable-nsclc","toripalimab","cisplatin","carboplatin"]},{"group":"trial","date":"2024","precision":"year","title":"NIAGARA reported","note":"EFS HR 0.68; OS HR 0.75.","from":"niagara","refs":["urothelial","muscle-invasive-bladder-cancer","durvalumab"]},{"group":"trial","date":"2024","precision":"year","title":"NORPACT-1 reported","note":"Alive at 18 months: 60 percent with neoadjuvant FOLFIRINOX against 73 percent with upfront surgery (p 0.032); median overall survival 25.1 against 38.5 months (hazard ratio 1.52, p...","from":"norpact-1","refs":["resectable-pdac","pancreatic","folfirinox","fluorouracil"]},{"group":"trial","date":"2024","precision":"year","title":"PACE-B reported","note":"5-year biochemical or clinical failure-free 95.8% (SBRT) vs 94.6% (conventional), non-inferior.","from":"pace-b","refs":["prostate","prostate-low-risk","prostate-intermediate-risk"]},{"group":"trial","date":"2024","precision":"year","title":"PACIFIC-2 reported","note":"Concurrent durvalumab with chemoradiotherapy did not significantly improve progression-free survival over chemoradiotherapy alone.","from":"pacific-2","refs":["stage-iii-unresectable-nsclc","nsclc","lung-cancer","durvalumab"]},{"group":"trial","date":"2024","precision":"year","title":"PARTIQoL reported","note":"No difference between protons and IMRT in EPIC bowel quality of life at 24 months (primary endpoint, p=0.836) or in urinary or sexual function; five-year progression-free survival...","from":"partiqol","refs":["prostate"]},{"group":"trial","date":"2024","precision":"year","title":"PARTNER reported","note":"Germline BRCA group: three-year survival 100 percent (39 patients, one relapse) with the gap schedule versus 88 percent (45 patients, nine relapses) with chemotherapy alone (Univer...","from":"partner","refs":["tnbc","tnbc-early","olaparib","carboplatin"]},{"group":"trial","date":"2024","precision":"year","title":"PATINA reported","note":"Palbociclib added to maintenance anti-HER2 and endocrine therapy lengthened progression-free survival.","from":"patina","refs":["breast-her2-positive","breast-hr-positive","breast-cancer","palbociclib"]},{"group":"trial","date":"2024","precision":"year","title":"Pembrolizumab with or without anetumab ravtansine in mesothelin-positive pleural mesothelioma (NCI) reported","from":"nci-anetumab-pembrolizumab-mpm","refs":["mesothelioma","anetumab-ravtansine","pembrolizumab"]},{"group":"trial","date":"2024","precision":"year","title":"PhALLCON reported","note":"MRD-negative CR 34.4% vs 16.7%.","from":"phallcon","refs":["all-leukemia","ponatinib","imatinib"]},{"group":"trial","date":"2024","precision":"year","title":"PHERGain reported","note":"3-year iDFS 95.4% in the PET-adapted arm; ~1 in 3 spared chemotherapy.","from":"phergain","refs":["breast-her2-positive","her2-positive-early-breast-cancer","trastuzumab","pertuzumab"]},{"group":"trial","date":"2024","precision":"year","title":"Ponsegromab phase 2 in cancer cachexia reported","note":"Placebo-adjusted weight gain 2.81 kg at 400 mg over 12 weeks; improved appetite and activity.","from":"ponsegromab-phase-2","refs":["nsclc","pancreatic","colorectal"]},{"group":"trial","date":"2024","precision":"year","title":"postMONARCH reported","note":"PFS 6.0 vs 5.3 months, HR 0.73.","from":"postmonarch","refs":["breast-hr-positive","hr-positive-metastatic-post-cdk46","abemaciclib"]},{"group":"trial","date":"2024","precision":"year","title":"RADICALS-HD reported","note":"Ten-year metastasis-free survival 78.1 percent with 24 months of androgen deprivation against 71.9 percent with 6 months (hazard ratio 0.773, 95 percent confidence interval 0.612 t...","from":"radicals-hd","refs":["prostate","prostate-high-risk","prostate-bcr","bicalutamide"]},{"group":"trial","date":"2024","precision":"year","title":"RAMP 201 reported","note":"ORR 44%, median PFS 19.6 months in KRAS-mutant LGSOC.","from":"ramp-201","refs":["ovarian","avutometinib-defactinib"]},{"group":"trial","date":"2024","precision":"year","title":"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small...","from":"nct04154956","refs":["nsclc","tusamitamab-ravtansine","docetaxel"]},{"group":"trial","date":"2024","precision":"year","title":"SENOMAC reported","note":"Five-year recurrence-free survival 89.7 percent with sentinel node biopsy alone against 88.7 percent with completion axillary clearance (hazard ratio 0.89, 0.66 to 1.19, non-inferi...","from":"senomac","refs":["breast-cancer","breast-hr-positive","breast-her2-positive","tnbc"]},{"group":"trial","date":"2024","precision":"year","title":"SHAPE (CCTG CX.5) reported","note":"Simple hysterectomy was non-inferior to radical hysterectomy for three-year pelvic recurrence in low-risk early cervical cancer, with fewer urinary complications.","from":"shape","refs":["early-cervical-cancer","cervical"]},{"group":"trial","date":"2024","precision":"year","title":"SPLASH reported","note":"rPFS HR 0.71; interim OS HR 1.11.","from":"splash","refs":["prostate","prostate-mcrpc","lu177-psma-it"]},{"group":"trial","date":"2024","precision":"year","title":"STARGLO reported","note":"OS HR 0.62; FDA CRL 2025 over applicability.","from":"starglo","refs":["dlbcl","glofitamab"]},{"group":"trial","date":"2024","precision":"year","title":"Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan reported","from":"nct04956692","refs":["nsclc","sclc","pembrolizumab","paclitaxel"]},{"group":"trial","date":"2024","precision":"year","title":"Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in S...","from":"nct03801525","refs":["cll","umbralisib","venetoclax"]},{"group":"trial","date":"2024","precision":"year","title":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs reported","from":"nct04711135","refs":["pheochromocytoma-paraganglioma","lutathera"]},{"group":"trial","date":"2024","precision":"year","title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET reported","from":"nct03972488","refs":["neuroendocrine","small-intestinal-net","pancreatic-net","grade-3-net"]},{"group":"trial","date":"2024","precision":"year","title":"SunRISe-1 reported","note":"CR 82%; 51% in CR at 12 months.","from":"sunrise-1","refs":["urothelial","tar-200"]},{"group":"trial","date":"2024","precision":"year","title":"SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma reported","from":"nct04205630","refs":["endometrial","trastuzumab-duocarmazine"]},{"group":"trial","date":"2024","precision":"year","title":"TiNivo-2 reported","note":"PFS HR 1.10; no benefit from nivolumab rechallenge.","from":"tinivo-2","refs":["rcc","tivozanib","nivolumab"]},{"group":"trial","date":"2024","precision":"year","title":"Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual...","from":"nct02762266","refs":["hcc","ethiodized-oil"]},{"group":"trial","date":"2024","precision":"year","title":"TRIANGLE reported","note":"Three-year failure-free survival 88 percent with ibrutinib added to induction, transplant and maintenance against 72 percent with standard induction and transplant (hazard ratio 0...","from":"triangle","refs":["mantle-cell-lymphoma","non-hodgkin-lymphoma","ibrutinib","rituximab"]},{"group":"trial","date":"2024","precision":"year","title":"TrilynX reported","note":"EFS 19.4 vs 33.1 months (worse with xevinapant).","from":"trilynx","refs":["head-and-neck","hpv-negative-head-and-neck-cancer","xevinapant"]},{"group":"trial","date":"2024","precision":"year","title":"Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) r...","from":"nct04703192","refs":["peripheral-t-cell-lymphoma","non-hodgkin-lymphoma"]},{"group":"regulatory","date":"2024-01-19","precision":"day","title":"Axicabtagene ciloleucel: label change (US)","note":"Class boxed warning for T-cell malignancies","from":"axicabtagene-ciloleucel","refs":[]},{"group":"regulatory","date":"2024-01-19","precision":"day","title":"Ciltacabtagene autoleucel: label change (US)","note":"Class boxed warning for T-cell malignancies","from":"ciltacabtagene-autoleucel","refs":[]},{"group":"guideline","date":"2024-02","precision":"month","title":"ESMO ESMO CPG early breast cancer 2024 (Loibl et al.) for Triple-negative breast cancer (TNBC)","note":"2 rows added. Anchored to Annals of Oncology publication, 2024.","from":"tnbc","refs":["pembrolizumab","keynote-522","olaparib","olympia"]},{"group":"regulatory","date":"2024-02","precision":"month","title":"Vepdegestrant: designation (US)","note":"Fast Track designation","from":"vepdegestrant","refs":[]},{"group":"regulatory","date":"2024-02-16","precision":"day","title":"Lifileucel: approval (US)","note":"Accelerated approval, unresectable/metastatic melanoma after anti-PD-1 (C-144-01): first TIL therapy","from":"lifileucel","refs":[]},{"group":"regulatory","date":"2024-02-16","precision":"day","title":"Osimertinib: approval (US)","note":"First-line with chemotherapy (FLAURA2)","from":"osimertinib","refs":[]},{"group":"regulatory","date":"2024-02-20","precision":"day","title":"Teclistamab: label change (US)","note":"Biweekly dosing added for responders","from":"teclistamab","refs":[]},{"group":"regulatory","date":"2024-02-26","precision":"day","title":"Actinium-225 DOTATATE: filing (US)","note":"BMS completes RayzeBio acquisition ($4.1B)","from":"ryz101","refs":[]},{"group":"guideline","date":"2024-03","precision":"month","title":"NCCN 2024 update for Chronic lymphocytic leukaemia","note":"1 row added. Anchored to FDA accelerated approval of lisocabtagene maraleucel for CLL after BTK and BCL-2 inhibitors, March 2024 (TRANSCEND CLL 004).","from":"cll","refs":["lisocabtagene-maraleucel","transcend-cll-004"]},{"group":"guideline","date":"2024-03","precision":"month","title":"NCCN 2024 updates for Bladder & urothelial cancer","note":"1 row recategorised, 1 row added. Anchored to FDA approvals of enfortumab vedotin with pembrolizumab (December 2023, EV-302) and nivolumab with gemcitabine-cisplatin (March 2024, C...","from":"urothelial","refs":["enfortumab-vedotin","pembrolizumab","ev-302","nivolumab"]},{"group":"regulatory","date":"2024-03","precision":"month","title":"Tislelizumab: approval (US)","note":"Second-line ESCC (RATIONALE-302)","from":"tislelizumab","refs":[]},{"group":"regulatory","date":"2024-03","precision":"month","title":"Zolbetuximab: approval (Japan)","note":"World-first approval","from":"zolbetuximab","refs":[]},{"group":"regulatory","date":"2024-03","precision":"month","title":"Zongertinib: designation (US)","note":"Breakthrough Therapy designation","from":"zongertinib","refs":[]},{"group":"regulatory","date":"2024-03-01","precision":"day","title":"Amivantamab: approval (US)","note":"First-line exon 20 insertion with chemotherapy (PAPILLON)","from":"amivantamab","refs":[]},{"group":"regulatory","date":"2024-03-06","precision":"day","title":"Inotuzumab ozogamicin: label change (US)","note":"Paediatric expansion","from":"inotuzumab-ozogamicin","refs":[]},{"group":"regulatory","date":"2024-03-14","precision":"day","title":"Lisocabtagene maraleucel: approval (US)","note":"First CAR-T in CLL (TRANSCEND CLL 004), accelerated","from":"lisocabtagene-maraleucel","refs":[]},{"group":"regulatory","date":"2024-03-19","precision":"day","title":"Ponatinib: approval (US)","note":"Frontline Ph+ ALL (PhALLCON), accelerated","from":"ponatinib","refs":[]},{"group":"regulatory","date":"2024-03-22","precision":"day","title":"Mirvetuximab soravtansine: approval (US)","note":"Full approval with OS benefit (MIRASOL)","from":"mirvetuximab-soravtansine","refs":[]},{"group":"regulatory","date":"2024-03-25","precision":"day","title":"Odronextamab: complete response letter (US)","note":"CRLs for DLBCL and FL, confirmatory trial enrolment status","from":"odronextamab","refs":[]},{"group":"regulatory","date":"2024-04-05","precision":"day","title":"Ciltacabtagene autoleucel: approval (US)","note":"Relapsed myeloma after ≥1 prior line, lenalidomide-refractory (CARTITUDE-4)","from":"ciltacabtagene-autoleucel","refs":[]},{"group":"regulatory","date":"2024-04-05","precision":"day","title":"Trastuzumab deruxtecan: approval (US)","note":"HER2 IHC3+ solid tumours, tumour-agnostic (accelerated)","from":"trastuzumab-deruxtecan","refs":[]},{"group":"regulatory","date":"2024-04-18","precision":"day","title":"Tisagenlecleucel: label change (US)","note":"Class boxed warning for T-cell malignancies","from":"tisagenlecleucel","refs":[]},{"group":"regulatory","date":"2024-04-23","precision":"day","title":"Lutetium-177 dotatate: approval (US)","note":"Paediatric patients ≥12 years","from":"lutathera","refs":[]},{"group":"regulatory","date":"2024-04-29","precision":"day","title":"Tisotumab vedotin: approval (US)","note":"Full approval with OS benefit (innovaTV 301)","from":"tisotumab-vedotin","refs":[]},{"group":"regulatory","date":"2024-05","precision":"month","title":"Camrelizumab + rivoceranib: complete response letter (US)","note":"First CRL: manufacturing inspection findings","from":"camrelizumab-rivoceranib","refs":[]},{"group":"regulatory","date":"2024-05","precision":"month","title":"Camrelizumab: complete response letter (US)","note":"Complete response letter for camrelizumab + rivoceranib in HCC (manufacturing/inspection)","from":"camrelizumab","refs":[]},{"group":"regulatory","date":"2024-05-16","precision":"day","title":"Tarlatamab: approval (US)","note":"Accelerated approval, ES-SCLC after platinum (DeLLphi-301)","from":"tarlatamab","refs":[]},{"group":"regulatory","date":"2024-05-23","precision":"day","title":"Shield: advisory committee (US)","note":"FDA advisory committee votes favourably","from":"shield","refs":[]},{"group":"regulatory","date":"2024-05-24","precision":"day","title":"Ivonescimab: approval (China)","note":"EGFR-mutant NSCLC after TKI, with chemotherapy (HARMONi-A)","from":"ivonescimab","refs":[]},{"group":"regulatory","date":"2024-05-29","precision":"day","title":"Selpercatinib: approval (US)","note":"Paediatric ≥2 years","from":"selpercatinib","refs":[]},{"group":"guideline","date":"2024-06","precision":"month","title":"NCCN 2024 updates for Melanoma","note":"2 rows added. Anchored to FDA accelerated approval of lifileucel (February 2024) and NADINA publication (NEJM, June 2024).","from":"melanoma","refs":["lifileucel","c-144-01","nivolumab","ipilimumab"]},{"group":"regulatory","date":"2024-06","precision":"month","title":"Actinium-225 PSMA agents: filing (US)","note":"AstraZeneca completes Fusion Pharmaceuticals acquisition; FPI-2265 phase 3 planned","from":"ac225-psma","refs":[]},{"group":"regulatory","date":"2024-06","precision":"month","title":"Daraxonrasib: designation (US)","note":"Breakthrough Therapy designation, previously treated metastatic PDAC","from":"daraxonrasib","refs":[]},{"group":"regulatory","date":"2024-06","precision":"month","title":"Letetresgene autoleucel: designation (US)","note":"Breakthrough Therapy for MRCLS","from":"letetresgene-autoleucel","refs":[]},{"group":"regulatory","date":"2024-06","precision":"month","title":"Lutetium-177 dotatate: label change (US)","note":"First-line label based on NETTER-2","from":"lutathera","refs":[]},{"group":"regulatory","date":"2024-06","precision":"month","title":"Zidesamtinib: designation (US)","note":"Breakthrough Therapy designation, ROS1+ NSCLC after prior ROS1 TKI","from":"zidesamtinib","refs":[]},{"group":"expected","date":"2024-06-14","precision":"day","title":"Tazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in): primary completion","note":"Actual primary completion date on ClinicalTrials.gov.","from":"tazemetostat-doxorubicin-es","refs":[]},{"group":"regulatory","date":"2024-06-14","precision":"day","title":"Blinatumomab: approval (US)","note":"Consolidation in CD19+ Ph-negative B-ALL regardless of MRD (E1910)","from":"blinatumomab","refs":[]},{"group":"regulatory","date":"2024-06-21","precision":"day","title":"Adagrasib: approval (US)","note":"KRAS G12C colorectal cancer with cetuximab (accelerated)","from":"adagrasib","refs":[]},{"group":"regulatory","date":"2024-06-26","precision":"day","title":"Patritumab deruxtecan: complete response letter (US)","note":"Complete response letter citing third-party manufacturing inspection","from":"patritumab-deruxtecan","refs":[]},{"group":"regulatory","date":"2024-07-29","precision":"day","title":"Shield: approval (US)","note":"PMA approval: first blood test for primary colorectal cancer screening (ECLIPSE)","from":"shield","refs":[]},{"group":"regulatory","date":"2024-07-30","precision":"day","title":"Daratumumab: approval (US)","note":"Dara-VRd induction/consolidation (PERSEUS)","from":"daratumumab","refs":[]},{"group":"guideline","date":"2024-08","precision":"month","title":"NCCN 2023-2024 updates for Endometrial cancer","note":"1 row recategorised. Anchored to FDA approvals of dostarlimab with carboplatin-paclitaxel for dMMR disease (July 2023, RUBY), pembrolizumab with carboplatin-paclitaxel (June 2024...","from":"endometrial","refs":["dostarlimab","pembrolizumab","durvalumab","ruby"]},{"group":"regulatory","date":"2024-08","precision":"month","title":"Ifinatamab deruxtecan: designation (US)","note":"Breakthrough Therapy designation, extensive-stage SCLC after platinum","from":"ifinatamab-deruxtecan","refs":[]},{"group":"regulatory","date":"2024-08","precision":"month","title":"Odronextamab: approval (EU)","note":"Conditional approval DLBCL and FL","from":"odronextamab","refs":[]},{"group":"regulatory","date":"2024-08","precision":"month","title":"Shield: approval (US)","note":"Medicare coverage under the blood-based CRC screening NCD","from":"shield","refs":[]},{"group":"regulatory","date":"2024-08-01","precision":"day","title":"Afamitresgene autoleucel: approval (US)","note":"Accelerated approval, MAGE-A4+ HLA-A*02+ advanced synovial sarcoma (SPEARHEAD-1): first TCR-T for a solid tumour","from":"afamitresgene-autoleucel","refs":[]},{"group":"regulatory","date":"2024-08-01","precision":"day","title":"Dostarlimab: approval (US)","note":"All-comer primary advanced/recurrent endometrial cancer with chemotherapy","from":"dostarlimab","refs":[]},{"group":"regulatory","date":"2024-08-06","precision":"day","title":"Vorasidenib: approval (US)","note":"Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12 (INDIGO): first targeted therapy for low-grade glioma","from":"vorasidenib","refs":[]},{"group":"regulatory","date":"2024-08-19","precision":"day","title":"Amivantamab: approval (US)","note":"First-line EGFR-mutant NSCLC with lazertinib (MARIPOSA)","from":"amivantamab","refs":[]},{"group":"guideline","date":"2024-09","precision":"month","title":"NCCN 2024 updates for Multiple myeloma","note":"1 row recategorised, 2 rows added. Anchored to FDA approvals of cilta-cel in the second line and ide-cel in the third line (April 2024, CARTITUDE-4 and KarMMa-3), D-VRd (July 2024...","from":"multiple-myeloma","refs":["ciltacabtagene-autoleucel","idecabtagene-vicleucel","cartitude-4","karmma-3"]},{"group":"guideline","date":"2024-09","precision":"month","title":"NCCN 2024 updates for Non-small-cell lung cancer","note":"3 rows added. Anchored to FDA approvals of osimertinib with chemotherapy (February 2024, FLAURA2), adjuvant alectinib (April 2024, ALINA), amivantamab with lazertinib (August 2024...","from":"nsclc","refs":["osimertinib","amivantamab","lazertinib","flaura2"]},{"group":"regulatory","date":"2024-09","precision":"month","title":"Cadonilimab: approval (China)","note":"First-line cervical cancer (COMPASSION-16)","from":"cadonilimab","refs":[]},{"group":"regulatory","date":"2024-09-12","precision":"day","title":"Atezolizumab: approval (US)","note":"Subcutaneous atezolizumab (Tecentriq Hybreza)","from":"atezolizumab","refs":[]},{"group":"regulatory","date":"2024-09-17","precision":"day","title":"Ribociclib: approval (US)","note":"Adjuvant stage II-III HR+/HER2- early breast cancer at high risk (NATALEE)","from":"ribociclib","refs":[]},{"group":"regulatory","date":"2024-09-19","precision":"day","title":"Amivantamab: approval (US)","note":"After osimertinib, with chemotherapy (MARIPOSA-2)","from":"amivantamab","refs":[]},{"group":"regulatory","date":"2024-09-20","precision":"day","title":"Isatuximab: approval (US)","note":"IMROZ frontline","from":"isatuximab","refs":[]},{"group":"regulatory","date":"2024-09-25","precision":"day","title":"Osimertinib: approval (US)","note":"Unresectable stage III after chemoradiation (LAURA)","from":"osimertinib","refs":[]},{"group":"guideline","date":"2024-10","precision":"month","title":"NCCN 2023-2024 updates for Gastric & gastro-oesophageal junction cancer","note":"2 rows added. Anchored to FDA approvals of pembrolizumab with chemotherapy for HER2-negative disease (November 2023, KEYNOTE-859) and zolbetuximab (October 2024, SPOTLIGHT and GLOW...","from":"gastric","refs":["pembrolizumab","keynote-859","zolbetuximab","spotlight-glow"]},{"group":"guideline","date":"2024-10","precision":"month","title":"NCCN 2024 updates for Cervical cancer","note":"2 rows added. Anchored to FDA approval of pembrolizumab with chemoradiation for FIGO 2014 stage III-IVA disease (January 2024, KEYNOTE-A18); INTERLACE publication (Lancet, October...","from":"cervical","refs":["pembrolizumab","keynote-a18","carboplatin","paclitaxel"]},{"group":"guideline","date":"2024-10","precision":"month","title":"NCCN 2024 updates for HR-positive / HER2-negative breast cancer","note":"2 rows added. Anchored to FDA approvals of adjuvant ribociclib (September 2024, NATALEE) and inavolisib (October 2024, INAVO120).","from":"breast-hr-positive","refs":["ribociclib","natalee","inavolisib","inavo120"]},{"group":"regulatory","date":"2024-10","precision":"month","title":"Raludotatug deruxtecan: filing (US)","note":"Merck co-development of R-DXd under the Daiichi Sankyo alliance","from":"raludotatug-deruxtecan","refs":[]},{"group":"expected","date":"2024-10-10","precision":"day","title":"GAIN: primary publication of the closed German trial of neoadjuvant gemcitabine-cisplatin before re-resection of incidental gallbladder cancer (completed 10 Oct...","note":"Watch item on the Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.","from":"gallbladder-cancer-roadmap","refs":["gain-igbc","incidental-gallbladder-cancer"]},{"group":"regulatory","date":"2024-10-10","precision":"day","title":"Inavolisib: approval (US)","note":"PIK3CA-mutant HR+/HER2- endocrine-resistant advanced breast cancer with palbociclib and fulvestrant (INAVO120)","from":"inavolisib","refs":[]},{"group":"regulatory","date":"2024-10-15","precision":"day","title":"Optune / Optune Pax (TTFields): approval (US)","note":"Optune Lua, metastatic NSCLC after platinum (LUNAR)","from":"optune","refs":[]},{"group":"regulatory","date":"2024-10-18","precision":"day","title":"Zolbetuximab: approval (US)","note":"SPOTLIGHT/GLOW; companion diagnostic VENTANA CLDN18 (43-14A)","from":"zolbetuximab","refs":[]},{"group":"regulatory","date":"2024-11","precision":"month","title":"Mirvetuximab soravtansine: approval (EU)","note":"EMA approval","from":"mirvetuximab-soravtansine","refs":[]},{"group":"regulatory","date":"2024-11","precision":"month","title":"Sacituzumab govitecan: withdrawal (US)","note":"Urothelial cancer indication voluntarily withdrawn after TROPiCS-04","from":"sacituzumab-govitecan","refs":[]},{"group":"regulatory","date":"2024-11","precision":"month","title":"Sacituzumab tirumotecan: approval (China)","note":"NMPA approval, pretreated advanced TNBC (OptiTROP-Breast01); first TROP2 ADC approved in China","from":"sacituzumab-tirumotecan","refs":[]},{"group":"regulatory","date":"2024-11-08","precision":"day","title":"Obecabtagene autoleucel: approval (US)","note":"FELIX; approved without REMS","from":"obecabtagene-autoleucel","refs":[]},{"group":"regulatory","date":"2024-11-15","precision":"day","title":"Revumenib: approval (US)","note":"Relapsed/refractory KMT2A-rearranged acute leukaemia, age ≥1: first menin inhibitor","from":"revumenib","refs":[]},{"group":"regulatory","date":"2024-11-20","precision":"day","title":"Zanidatamab: approval (US)","note":"Accelerated approval, previously treated HER2+ (IHC3+) biliary tract cancer (HERIZON-BTC-01)","from":"zanidatamab","refs":[]},{"group":"regulatory","date":"2024-12","precision":"month","title":"Tislelizumab: approval (US)","note":"First-line gastric/GEJ (RATIONALE-305)","from":"tislelizumab","refs":[]},{"group":"expected","date":"2024-12-02","precision":"day","title":"Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer: primary com...","note":"Actual primary completion date on ClinicalTrials.gov.","from":"nct05117242","refs":[]},{"group":"regulatory","date":"2024-12-03","precision":"day","title":"Sacituzumab tirumotecan: designation (US)","note":"Breakthrough Therapy designation, EGFR-mutant NSCLC after TKI","from":"sacituzumab-tirumotecan","refs":[]},{"group":"regulatory","date":"2024-12-04","precision":"day","title":"Durvalumab: approval (US)","note":"Limited-stage SCLC after chemoradiation (ADRIATIC)","from":"durvalumab","refs":[]},{"group":"regulatory","date":"2024-12-04","precision":"day","title":"Zenocutuzumab: approval (US)","note":"Accelerated approval, NRG1-fusion NSCLC and pancreatic adenocarcinoma (eNRGy): first therapy for NRG1 fusions","from":"zenocutuzumab","refs":[]},{"group":"regulatory","date":"2024-12-13","precision":"day","title":"Cosibelimab: approval (US)","note":"Approved for cSCC","from":"cosibelimab","refs":[]},{"group":"regulatory","date":"2024-12-20","precision":"day","title":"Encorafenib: approval (US)","note":"First-line BRAF V600E mCRC with cetuximab and mFOLFOX6 (BREAKWATER, accelerated)","from":"encorafenib","refs":[]},{"group":"regulatory","date":"2024-12-27","precision":"day","title":"Nivolumab: approval (US)","note":"Subcutaneous nivolumab (Opdivo Qvantig)","from":"nivolumab","refs":[]}]},"route":"/years/2024/","neighbours":{"year":[{"id":"2023","kind":"year","name":"2023 in oncology","route":"/years/2023/"},{"id":"2025","kind":"year","name":"2025 in oncology","route":"/years/2025/"}]}}